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Abstract
Cancer is a deadly malignant disease that is costly to treat and still impossible to cure.
Cancer treatments often come with side effects that impact the overall health of patients.
Breast cancer is the most common type of cancer in the United State and bladder cancer
mortality and recurrence rates are still high among cancer patients. Thus, safe and effective
regimens are needed to combat these diseases.
In this study, the safe and efficacious combination of gemcitabine, cisplatin, and
romidepsin (Gem plus Rom+Cis) to treat two types of cancer: bladder and breast cancer, was
formulated. In vitro data from this study revealed that the combination of Gem plus Rom+Cis
synergistically reduced cell vitality, clonogenic survival, invasion, and anchorage independent
growth of bladder and breast cancer cell lines. The tolerable drug doses and administration
schedules of Gem plus Rom+Cis for mice model were determined. Athymic nude mice (nu/nu)
treated with the triple combination showed no significant weight loss or sign of toxicity at the
end of studies. Gem plus Rom+Cis efficaciously controls the development of tumors in CDX
models. Results showed that breast and bladder CDXs treated with Gem plus Rom+Cis had
significantly smaller tumor sizes comparing to double combination of Gem plus Cis or
Rom+Cis or untreated control. Data from urothelial carcinoma studies revealed that the
apoptosis of bladder cancer cells was found to be enhanced through the ERK-Nox-1 pathway
via reactive oxygen species (ROS) induction. Furthermore, drug resistance was reduced due to
the suppression of glutathione (GSH) and possibly by reducing factors that associated with
epithelial to mesenchymal transition (EMT). The data also suggested that the combination
reduced invasiveness and anchorage independence in cancer cell lines as a consequence of
suppressing the expression levels of proteins that are related to metastasis and EMT process.
vi

In conclusion, this triple combination was revealed to be more effective in controlling
tumor development than double or mono anti-cancer therapy. Thus this combination should be
considered as an advanced regimen for cancer treatment that hopefully could be translated into
a clinical trial to reduce cancer-related mortality and improved quality of life for cancer
patients.
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Chapter 1
Background and overviews
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1.1 Overview of Cancer
Cancer is a disease that is defined by the aberrant and uncontrollable growth of cells and
the ability to invade outside the site of origin. Cancer is also constantly mutating and can rapidly
adapt to treatments. Hence, this makes cancer difficult to treat especially in the case of
recurrence.
Cancer is the 2nd leading cause of death in the United States [1, 2]. There were an
estimated 1,806,590 people diagnosed with cancer in 2020 and 606,520 people were estimated to
die from the disease [1]. The estimated expenditure of cancer care is projected to be $157 billion
in 2020 [3]. As stated, cancer is one of the most dangerous and expensive to treat. Therefore,
finding newer and more effective treatments for cancer is a priority for cancer research.
The two types of cancers central to this dissertation are breast cancers and bladder
cancers. Breast cancer is the most diagnosed cancer in the United States and there lacks an
efficacious targeted therapy for the triple negative subtype of breast cancer [1, 4]. Bladder
cancer is the 6th most diagnosed cancer with high mortality and recurrence rates [1, 5]. Thus it
would be beneficial to many patients to find an effective treatment for these types of cancer.

1.2 Breast cancer
1.2.1 Overview of breast cancer
Breast cancer is one of the most common cancers in the United States [1]. The estimated
new cases of breast cancer in 2020 is 279,100 cases, which is the highest among all types of
cancer [1]. Breast cancer occurs in different areas of the breast including the ducts, the lobules,
or the tissue in between. The risk of breast cancer increases with age, with the most frequent
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diagnoses at ages 55-64 [1]. Women who are diagnosed at an older age have a greater chance of
dying from this disease, as the median age of death from breast cancer is 68 years old [6].
The 5 year survival rate of all subtypes of breast cancer is 90% and it is the fourth leading cause
of cancer related death in the United States [1].

1.2.2 Classification of Breast cancer
The majority of breast cancers are adenocarcinomas - cancer that develops in the
glandular tissues [7]. Breast adenocarcinomas can be classified by the site of origins into ductal
(milk-ducts) and lobular (milk-producing glands) carcinomas [7]. The two types of breast cancer
can then be further classified by invasiveness: in situ (non-invasive) or invasive [7]. In situ
carcinomas are a malignant type of epithelial tumor that does not extend beyond the basement
membrane and does not exhibit any invasive qualities. Invasive carcinomas are carcinomas that
extend beyond the basement membrane.
Due to the current advances in molecular biology, invasive breast carcinomas can be
classified, by molecular subtypes, into five distinct subtypes based on the availability of estrogen
receptor (ER), progesterone receptor (PR), and epidermal growth factor 2 (ERBB2, formerly
called HER, shorted for human epidermal growth factor receptor 2). Breast cancers are
categorized into 5 subtypes: luminal A, luminal B, HER2-enriched, normal-like, and triple
negative [7-12].
Luminal-like breast cancer subtypes have gene expression profiles similar to the luminal
epithelial component of the breast [8]. Luminal-like subtypes are the most common subtypes
among breast cancer [7, 8]. Luminal-like breast cancer can be grouped into luminal A and
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luminal B [7-9]. Luminal A breast cancer cells lack the HER2 receptor (HER2 negative) and are
hormonal receptor (HR) positive (Estrogen-/Progesterone-Receptor positive) [7-9]. This type of
breast cancer has a lower proliferation rate as it has a low level of Ki-67, which is a proliferation
marker [7-9]. 5 year surval rate of luminal A is 94.1% [1]. This type of breast cancer responds
well to endocrine therapy since it has hormone receptors. Luminal A has better prognoses among
molecular subtypes of breast cancer.
Luminal B is hormonal receptor positive similar to luminal A, but the expressions of
hormonal receptors are lower than luminal A and HER2 receptor of luminal B can be either
negative or positive [8]. Luminal B has a higher proliferation rate and has worse prognoses than
luminal A [8, 10]. 5 yaear survival rate of this subtype is 90.4% [1]. Luminal B respond to
endocrine therapy as well as Luminal A due to the similarity of hormone receptors.
Normal-like breast cancer subtype has estrogen, progesterone receptors available on the
cell surface while lacks HER2 receptor similar to luminal A, but it has a similar gene expression
profile as found in normal breast cells [7]. Normal-like breast cancer is the least prevalent
subtype [8]. It has a high proliferation rate and is considered to have worse prognoses than
luminal A, but not as poor as HER-2 enriched subtype [7, 8].
HER2-enriched subtype has no expression of estrogen and progesterone receptors, but it
has overexpressed HER2 receptor [7, 8]. HER2-enriched subtype also has a high proliferation
rate and has worse prognoses than luminal breast cancers [7, 8, 11]. 5 year survival rate of HER2
enriched type is 83.6% [1]. HER2-enriched subtype also has a high recurrence rate [11].
Monoclonal antibody specifics to HER2 receptor, such as trastuzumab, can be used to treat this
subtype effectively [11].
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Triple negative breast cancer (TNBC) subtype, which got its name due to the lack of all
three types of receptors (estrogen, progesterone, and HER2 receptors), has a high proliferation
rate and high risk of local and regional relapse [7, 8]. This subtype has been considered the
hardest to treat because there is no distinguishable receptor as7 a target [7, 8, 12]. This
dissertation focuses on TNBC subtype as it has the lowest 5 years survival rate at 76.5%
compared to the 90% overall survival rate of all subtypes [2] and there is no targeted therapy for
this type of breast cancer [4], thus an efficacious regimen for this subtype of breast cancer is
currently needed.

1.2.3 Overview of breast cancer treatment
Treatment of breast cancer is dependent on the subtype of breast cancer a patient has.
For HR+/ERBB2- subtypes, endocrine therapy, which targets the estrogen promoted growth
tumor, is the primary treatment [4, 11-13]. Out of all the subtypes of breast cancer, the triple
negative type is the most difficult to treat. It has the poorest prognoses of all the breast cancer
subtypes and has the lowest 5 year survival rate at 76.5% [2]. The problem with TNBC is that
there is no specific target. Sequential single-agent chemotherapy of drugs, such as docetaxel,
paclitaxel, carboplatin, or cisplatin, are still prominently used to treat triple negative breast
cancer [4]. However, studies showed that combination therapy has a greater chance of improving
the overall response rate when compared to single-agent treatment [12]. The combination of
drugs that are traditionally used to treat breast cancer is cyclophosphamide, methotrexate, and
fluorouracil [5-FU] (CMF) [13-15].
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1.3 Bladder cancer
1.3.1 Overview of bladder cancer
Bladder cancer is one of the most common cancers in the United States. There are an
estimated 81,400 new cases of bladder cancer in 2020. With that number, bladder cancer was
ranked the 6th most common type of cancer in 2020. Bladder cancer patients have a 5 year
survival rate at 77.1% [1]. Although not as common as breast cancer, bladder cancer has a lower
5 years survival rate than breast cancer (70% vs. 90%). Bladder cancer also often develops
resistance to cisplatin-based therapy [1, 16]. Thus, it is important to find a treatment that can
effectively induce cell death and reduce drug resistance in bladder cancer.

1.3.2 Classification of bladder cancer
Bladder cancer can be categorized by cell morphology into 3 of the following types:
Urothelial carcinoma, Squamous cell carcinoma, and Adenocarcinoma. Urothelial carcinoma is
also called transitional cell carcinoma [5, 16]. This type of bladder cancer originates from
urothelial cells in the urinary tract. They account for 90% of all bladder cancer [5, 16].
Squamous cell carcinoma is, as the name suggests, developed from squamous cells. This type
accounts for about 4% of bladder cancer [5, 16]. Adenocarcinoma develops from glandular cells
and accounts for 2% of all bladder cancer [5, 16].
Urothelial carcinomas are the most abundant of all types of bladder cancer [5,16] and it
can be further categorized by their malignancy into non-muscle invasive bladder cancer and
muscle invasive bladder cancer. Non-muscle invasive bladder cancer only grows in the inner
layer of the bladder cells. Thus, this type tends to not pose a threat to the survival of patients.
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However, it can recur; thus, long term surveillance of recurrence is still needed for the patients
[16, 17]. Muscle invasive bladder cancer grows into the deep layer of the bladder wall. This type
of bladder cancer is aggressive and can become metastatic; thus, it is considered to have poorer
prognoses and is more difficult to treat than the non-muscle invasive type [16, 17].

1.3.3 Overview of bladder cancer treatment
The initial step of non-muscle invasive cells is transurethral resection. Intravesical
chemotherapy with mitomycin, epirubicin, or gemcitabine is recommended after resection [16].
Standard treatment for muscle invasive bladder cancer is radical cystectomy with neo adjuvant
therapy of a platinum based drug, such as cisplatin [16, 18]. A combination of gemcitabine and
cisplatin or methotrexate-vinblastine-doxorubicin-cisplatin are considered effective ways to treat
muscle invasive bladder cancer [18].
Cancer becomes deadlier and harder to treat when in a metastatic state [1, 19]. The 5 year
survival rate of bladder cancer drops drastically from 70% when it is in the localized state to 5%
when in metastasis state, while TNBC drops from 91.2% to 11.5% [1]. The next section will
discuss invasion and metastasis.

1.4 Invasion and Metastasis
1.4.1 Overview of invasion and metastasis
Metastasis is a primary cause of death when cancer treatment fails. It is
responsible for 90% of cancer related death [19]. Invasion-metastasis cascade is a complicated
biological process. The first step of metastasis begins when cancer cells lose their epithelial
7

polarity and gain mesenchymal polarity through the process known as the epithelial to
mesenchymal transition (EMT). In the second step of metastasis, cancer cells invade adjacent
tissues by releasing proteases to breakdown the extracellular matrix and basement membrane. In
the third step, cancer cells move from the tissue of origin into blood and/or lymphatic vessels
(i.e. intravasation). In the fourth step, cancer cells escape from vessels (i.e. extravasation) and
migrate into new tissue. In the fifth step, the metastatic colony proliferates at the new tissue site
(Fig. 1.3) [19-21].
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Figure 1.1 Metastasis process. Step 1: cancer cells lose their epithelial polarity and gain mesenchymal polarity
through the EMT process. Step 2: cancer cells invade adjacent tissues by releasing proteases to breakdown the
extracellular matrix and basement membrane. Step 3: cancer cells move into blood vessels (intravasation) and able
to survive. Step 4: cancer cells escape from vessels (extravasation) and migrate into new tissue. Step 5: the
metastatic colony proliferates at the new tissue site [19-21].
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1.4.2 Metastasis-associated factors
The molecular mechanisms crucial to the metastasis processes are grouped into the
alteration of cell surface adhesion, EMT, production of proteolytic enzymes, and angiogenesis
[20]. Each process has many genes and proteins involved that can be considered as therapeutic
targets.
Cell surface adhesion proteins
Epithelial cells bind to adjacent cells using adhesion proteins [20-23]. For tumor cells to
detach from the original site, they have to reduce cell-cell adhesion. Thus, alteration of cell
surface adhesion proteins is usually associated with invasion and metastasis as cells are easier to
disseminate from the original positions [20-22]. Cadherins are transmembrane adhesion proteins
that mediate cell-cell binding [20-22]. E-cadherin is a member of this group and it is one of the
most well-studied adhesion proteins [20-22]. Loss or mutation of E-cadherin is associated with
invasiveness and metastasis in many types of cancer including bladder, breast, lung, and
pancreas [22-26]. The loss of E-cadherin is also associated with the EMT process [27-29].
EMT related proteins
EMT process is essential to metastasis as cells in the mesenchymal state gain more
motility, plasticity, and survivability when compared to cells that are in the epithelial state [20,
21, 27, 28]. Gaining EMT therefor helps metastatic cancer cells in the intravasation and
extravasation processes [47]. EMT is a multi-step process in which cells lose the characteristics
of epithelial cells and acquire the characteristics of mesenchymal cells [28]. EMT was originally
found to be involved in embryonic development and wound healing, but later was found to be
correlated with tumor invasion and metastasis [28]. This process is also associated with the
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induction of stem cell-like properties, prevention of apoptosis and senescence, and contributes to
drug resistance [28]. During the EMT process, epithelial cells lose epithelial cell markers, such
as E-cadherin, and alpha-catenin. Then, cells gain mesenchymal related markers, such as
vimentin. Vimentin is a type III intermediate filament (IF) protein that is abundantly expressed in
normal mesenchymal cells. Its role in normal cells is to maintain cellular integrity by providing
support and anchorage position to organelles and provides resistance against mechanical stress
[29, 30]. As a result of EMT, epithelial cells lose cell-cell adhesion and obtain the stem cell-like
characteristics, cell motility, and survivability of mesenchymal cells. Many studies associate
EMT markers with higher grade tumors, drug resistance, and poor prognosis [28, 29]. Deletion
of genes related to EMT resulted in decreasing in invasiveness and inhibition of metastasis of
tumor cells [27].
Proteolytic enzymes
For cancer cells to mobilize through tissues, they have to digest the surrounding
extracellular matrix (ECM) by producing and releasing proteolytic enzymes [31, 32]. ECM
forms connective tissues as a physical barrier to metastatic cancer cells. Cancer cells need to
secrete protease to break them down in order to move from one tissue to another [31, 32]. Thus,
proteolytic enzymes, such as protease, are important in many steps of invasion and metastasis as
the barrier needs to be broken down for tumor cells to be mobilized [19-21, 32, 33]. The most
well-studied groups of proteases are serine protease urokinase plasminogen activator (uPA),
cysteine protease (CA), and matrix metalloproteinase (MMP) [32]. uPA activates degradation of
the ECM by converting inactive plasminogen to plasmin, which is a protease that effectively
digests ECM [32, 33]. CA is involved in degrading the basement membrane, a specialized
extracellular matrix that lines the surfaces of connective tissues. Even though the function of CA
11

is known, the role of it in cancer progression is still uncertain [32, 34]. Matrix metalloproteinase
(MMP) is a group of enzymes that are responsible for the degradation of extracellular matrix
proteins [32, 35]. Normally MMPs are involved in organogenesis; thus, the expression of MMPs
in adult tissues is relatively low [33, 36]. Increased MMPs expression is usually involved in
inflammatory processes, tumor growth, and metastasis. High expression of MMP9 is associated
with lymph node metastasis and higher tumor stages in breast cancer [21, 31, 32]. Inhibition of
MMPs resulted in arresting tumor growth and spread [37].
Angiogenesis factors
Angiogenesis is an important process that cancer utilizes to obtain more nutrition and
oxygen for growth and colonization of distant organs [38]. Tumor growth is limited without
blood vessels bringing oxygen and nutrients; without blood circulation, tumors stop growing
after becoming 1-2 mm2 in diameter [39]. Metastatic tumors need to form blood vessels in order
to proliferate after extravasation and established a colony in distant organs [39, 40].
Consequently, disrupting tumor blood vessels can lead to cell death [38]. Thus, angiogenesis is a
necessary process for tumor growth, survival, and metastasis [38, 39]. Angiogenesis related
genes are good candidates for cancer markers since blood vessels only need to be formed in
adults on a few occasions, such as wound healing or tissue repair. Genes that are involved in
angiogenesis are angiogenin, vascular endothelial growth factor (VEGF), platelets derived
growth factors (PDGF), and interleukins (ILs) [38, 39].
Because cancer is a metastatic disease caused by mutations, alterations in signaling
pathways make cancer cells distinguishable from non-cancer cells [19-21]. Thus, targeting
proteins in aberrant pathways can be an effective approach for developing a novel cancer
treatment regimen. The next section is going to explore the targetable pathways of cancer.
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1.5 Targetable aberrant pathway of cancers
Cancer often has mutations in the genes that are associated with pathways that facilitate
cell growth, survival, or cell death suppression. Targeting or exploiting the overexpressed or
mutated proteins that are associated with aberrant pathways is one way to specifically target
cancer while doing as little harm as possible to normal cells.

1.5.1 MAPK pathway
The Mitogen-Activated Protein Kinase (MAPK) pathway is also known as the Ras-RafMEK-ERK pathway. The MAPK pathway begins with the activation of Ras, stimulated by the
upstream receptor (e.g. receptor tyrosine kinases), by switching from guanosine diphosphate
(GDP)-bound Ras (inactive) to guanosine triphosphate (GTP)-bound Ras (active). GTP-bound
Ras then binds and activates Raf kinase [18, 41]. Activated Raf phosphorylates mitogenactivated protein kinase kinase (MEK), which in turn activates extracellular-signal-regulated
kinase (ERK) by phosphorylation [41, 42]. Activated ERK phosphorylates many downstream
targets that are involved in many cellular processes including cell proliferation, cell survival, cell
invasion, and cell mortality (Fig.1.1) [43, 44]. Mutation of the Ras gene occurs in about 30% of
all tumors and ERK activity is upregulated in many cancer types [45, 46]. Thus, many
researchers study this pathway to find a good target for anti-cancer drug development.
Despite the fact that most Ras mutations are associated with poorer cancer prognoses [4346], previous studies have shown that activation of ERK in Ras mutated cancer could facilitate
cancer cell killing [47-52]. The studies showed activated ERK can preferentially induce
apoptosis in oncogenic H-Ras expressing cell lines by increasing the production of reactive
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oxygen species through the nicotinamide adenine dinucleotide phosphate oxidase (NADPH)
oxidases (Nox) protein family downstream of ERK [47-52]. Thus, activation of MEK and ERK
does not always lead to cancer cell growth and survival, but also could lead to cellular apoptosis.

Figure 1.2 MAPK signaling pathway. Upstream receptor activates Ras by switching from GDP-bound to
GTP- bound Ras. Then, Ras activates Raf, Raf activates MEK, and MEK activates ERK. ERK then
phosphorylates downstream targets that are involved in multiple cellular processes [41-44]. Arrows indicate
activation.
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1.5.2 Reactive Oxygen Species
Reactive oxygen species (ROS) are oxygen-containing chemical species that have
reactive chemical properties. Examples of ROS are superoxide, hydroxyl radical, and hydrogen
peroxide. In biological systems, ROS are generated by many pathways as a signaling molecule
[53]. ROS are signaling molecules that, depending on the level of ROS availability, could
stimulate cell proliferation, trigger stress response, increase genetic instability, or induce
apoptosis and alter drug-sensitivity in cancer cells [54].
Cancer cells increase intrinsic ROS production due to oncogenic induction, increased
metabolic activity, and mitochondrial malfunction [52, 53]. ROS are also a highly reactive
molecule that can generate oxidative damages to a large number of molecules within cells
including inorganic molecules, proteins, lipids, carbohydrates, and nucleic acids [54]. Thus, ROS
are also identified as a major contributor to cellular damage in biological organisms [54].
High concentration of ROS triggers apoptosis mainly through two mechanisms, indirectly
by damaging DNA, lipids, and proteins within cells, and directly by the activation of apoptosisrelated pathways. ROS induces apoptosis through the activation of various MAP kinases, such as
Erk1/2, SAPK/JNK, and p38 [56-58].
Two major sources of ROS production are the mitochondria and the NADPH-oxidase
enzyme [55]. Mitochondria are a major contributor to endogenous ROS production. About 1% of
oxygen consumed by mitochondria is converted to superoxide through the tricarboxylic acid
(TCA) cycle and electron transport chain [57]. Most of the superoxide from the mitochondria is
converted to H2O2 by manganese superoxide dismutase (MnSOD). ROS from mitochondria are
involved in many pro-survival signals, including cell differentiation, oxygen sensing, and the
adaptive immune system [57]. Mitochondrial ROS has a damaging role as well as a signaling
15

role. Deregulation of mitochondrial ROS is associated with the initiation of many types of cancer
including chronic lymphocytic leukemia, acute myeloid leukemia, and breast cancer [57].
Nox is a family of transmembrane proteins that transfer electron across membranes to
produce superoxide, which is rapidly converted to H2O2. The Nox family consists of 7 Nox
isoforms; Nox 1-5 and dual oxidase (Duox) 1-2 [56]. All 7 isotypes are similar in structure, but
they are regulated differently; for example, Nox-1 expression is induced by platelet-derived
growth factor (PDGF), while Nox-4 can be induced by transforming growth factor (TGF)-β1 and
tumor necrosis factor (TNF)-α [56]. Nox generated ROS often acts as a secondary messenger for
growth factor stimulations, which regulate many of the cells’ biological functions including hostdefense mechanisms, cellular homeostasis, gene regulation, cell death, and senescence [56, 57].
ROS generated by Nox are tightly regulated by the activity of antioxidants and ROS-scavenging
enzymes [55].
Due to the variety of roles that ROS perform, ROS homeostasis is essential for regular
cell signaling and survival. Many enzymatic and non-enzymatic anti-oxidant molecules are
involved in regulating ROS, such as glutathione, flavonoids, vitamin A, C and E, superoxide
dismutase (SOD), glutathione reductase, and thioredoxin (TRX) [54-56].
Targeting ROS in cancer therapy can be done either by inducing or reducing ROS
production. Ind Inducing ROS production increases oxidative-stress induced tumor cell death
[58, 59]. High concentration of ROS in cells exhausts the anti-oxidation capacity and causes
irreversible damage to cellular components, which results in the activation of programmed cell
death [59].
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1.5.3 Unfolded protein response pathway
The endoplasmic reticulum (ER) is an intracellular organelle that is responsible for
protein folding. Increased ER stress results in the accumulation of misfolded or unfolded
proteins; examples of cellular stress are nutrient deprivation, calcium depletion, oxidative stress,
and DNA damage [60-63]. If left unresolved, the accumulation of unfolded proteins can lead to
apoptosis [64-66]. Cancer cell metabolism typically results in hypoxia, pH changes, and
restriction of the nutrient supply, which can trigger the unfolded protein response (UPR)
pathway. The UPR pathway is often activated in order to resolve the accumulation of unfolded
proteins. Furthermore, chemotherapy can also trigger the UPR pathway to promote survival [4346].
Binding immunoglobulin protein (BiP), also known as 78 kDa glucose-regulated protein
(GRP78), is a chaperone protein that prevents misfolded proteins from being transported or
aggregated [60-63]. It is located in the lumen of the ER. BiP acts as the master regulator for the
UPR pathway [65]. It plays a key role in the regulation of the UPR by regulating three important
downstream transmembrane proteins: protein kinase R (PKR)-like endoplasmic reticulum kinase
(PERK), inositol-requiring enzyme-1α (IRE1α), and transmembrane activating transcription
factor 6 (ATF6) [65]. When misfolded or unfolded proteins are absent, BiP binds to PERK,
IRE1α, or ATF6 to prevent their activation; when misfolded or unfolded proteins are present,
BiP releases the three proteins in order to bind to misfolded or unfolded proteins, which allows
PERK, IRE1α, and ATF6 to be activated (Fig.1.2) [63-68].
The PERK arm of the UPR pathway induces translational arrest by promoting
phosphorylation of the Eukaryotic Initiation Factor 2 alpha (eIF2α). This results in the inhibition
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of global protein synthesis and activates apoptosis by upregulating transcription factor 4 (ATF4)
and the C/EBP Homologous Protein (CHOP) pathway (Fig.1.2) [69].
Activation of IRE1α leads to cleavage of the mRNA of X-box-binding protein 1(XBP1).
This results in the translation of the stable, spliced form XBP1-s that influences the transcription
factors involved in the ER-associated degradation (ERAD) process (Fig.1.2) [68].
ATF6 is a basic leucine zipper transcription factor. When released from BiP, it is
translocated from the ER to the Golgi apparatus to be cleaved by Site-1 protease (S1P) and Site-2
protease (S2P) to generate the cleaved ATF6 active form. This form can be translocated to the
nucleus, inducing the transcription of genes that facilitate protein folding and maturation
(Fig.1.2) [69].
The outcome of the UPR pathway is dependent on many factors. In general, UPR is
meant to have protective roles as it aims to relieve damage and restore protein function.
However, if the accumulation of unfolded proteins is beyond repair, UPR may trigger the
apoptotic pathway. Thus, under stress, BiP could be pro-apoptotic or pro-survival depending on
the level of unfolded proteins present in the cell [62]. However, how UPR invokes apoptosis is
still poorly addressed in the literature. Recently, BiP has become one of the potential targets of
anti-cancer drugs, since cancer is more dependent on the UPR pathway to survive than noncancerous cells due to greater ER stress caused by a higher rate of protein synthesis [65, 66].
Targeting aberrant pathways specific to cancer is potentially more efficient than
traditional chemotherapeutic treatment while being less harmful to normal cells. However,
targeting only one pathway at a time is often not enough to eliminate cancer, since alternative
pathways can be upregulated to compensate for the targeted pathway and cause resistance to the

18

therapy [70-72]. Using multiple drug combinations for treating cancer often leads to a more
favorable outcome. The topic of drug combination therapy will be discussed in the next section.

Figure 1.3 Unfolded protein response signaling pathway. (a) Unfolded proteins are absent, BiP binds to PERK,
IRE1α or ATF6 to prevent their activation. (b) Unfolded proteins are present, BiP releases the three proteins in order
to bind to unfolded proteins, which allows PERK, IRE1α, and ATF6 to be activated [63-68].
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1.6 Drug combination therapy
Many reagents have the potential to kill cancer cells when used as a single therapeutic
reagent at high doses. Yet, higher doses often come with higher toxicity and side effects; thus,
this prevents them from being used as a therapeutic drug. Additionally, drug resistance and
recurrence are often observed after single drug therapy due to the activation of compensatory
pathways [94-96]. To solve this problem, a combination of drugs that has different mechanisms
of action can be used to target multiple pathways at the same time. Combination therapies have
become standard treatment for many types of cancer, including breast cancer and bladder cancer
[13-18]. Typically, combination therapies are a combination of chemotherapeutic drugs
composed of drugs that have no overlapping mechanism of action in order to maximize tumor
response and prevent drug resistance [73]. However, every drug also comes with toxicity.
Combining multiple drugs could also not only enhance the effect on tumor response but also
potentially enhance toxicity [73]. Thus, combined drugs should be able to control tumor growth
in a synergistic manner, rather than an additive manner in order to effectively control tumors and
to be able to reduce therapeutic dosage to lessen potential toxicities. The synergistic combination
of chemotherapeutic reagents can overcome the toxicity and side effects associated with using
single reagents at high doses [71]. Minimizing drug resistance and recurrence are also benefits
from a synergistic combination [71, 72]. Another potential benefit of combination therapy, with
FDA approved drugs, is that it may be able to garner FDA approval more quickly and decrease
the cost of drug development by repurposing existing drugs.
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1.6.1 Synergistic effect of drug combination
The goal of formulating drug combinations is to achieve a synergistic therapeutic effect
with dose reduction. The effects of drug combinations can be categorized into additive,
synergistic, and antagonistic. An additive effect occurs when a combination of two or more drugs
produces an effect that is equal to the sum of the effect of each drug. For example, drug A killed
30% of cells and drug B killed 30% of cells; when combined, combination AB killed 60% of
cells. A synergistic effect is when two or more drugs enhance efficacy when combined. For
example, drug A killed 30% of cells and drug B killed 30% of cells; when combined,
combination AB killed 80%, this combination will be considered synergistic. An antagonistic
effect is when two or more drugs antagonize each other, i.e. drug A (30% cell killing) + B (30%
cell killing) killed only 30% of cells when combined.
However, the additive effect is not simply an arithmetic sum of effects of two drugs; for
example, if drug A killed 60% of the cells and drug B killed 60% of the cells, the result cannot
be 120% cell killing since the maximum killing capacity is 100%. Therefore, computational
methods were developed to determine whether the effects of a given drug combination are
additive, synergistic, or antagonistic. In 1984, John Chou and Paul Talalay developed a
computational approach to quantify the synergistic effect of drug combination and introduce the
combination index (CI) theorem [74].
Calculation of CI is based on the following CI equation::
CI=

(𝐷)1
(𝐷𝑥)1

+

(𝐷)2
(𝐷𝑥)2

=

𝐷1
1
𝑓𝑎
𝑚1
(𝐷𝑚 )1 〖[
])
1−𝑓𝑎

+
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𝐷2
1
𝑓𝑎
𝑚2
(𝐷𝑚 )2 〖[
])
1−𝑓𝑎

[74]

Where 𝑓𝑎 = fraction of the system that is affected by drug, (𝐷)1 , (𝐷)2 =dose of drug 1,
drug 2, (𝐷)𝑚1 , (𝐷)𝑚2 = dose of drug 1, drug 2 required to produce a median effect (IC50), and
𝑓

𝑎
m = the slope of the median-effect plot, in which y = log (1−𝑓𝑎
) and X = log (D).

For n Drug combination: CI = ∑𝑛𝑖=1(𝐷)𝑖/(𝐷𝑥)𝑖 [74]
The CI theorem offers quantitative definition for the additive effect as CI=1, the
synergistic effect as CI<1, and the antagonistic effect as CI > 1 [74, 75]. This method is widely
used because it provides a quantitative definition of the synergistic effect and it allows small
numbers of data points for calculation. For convenience, CompuSyn software for CI calculation
was developed by Chou and Martin and is available for free (76).

16.2 Example of drug combinations for cancer treatment
Using combination therapy has many advantages over single drug treatment [71-73].
Bladder cancer is susceptible to cisplatin, however, using only cisplatin for treatment causes
cancer to become resistant to the drug [18].To fix this problem, cisplatin was used in
combination with other drugs. For example, a combination of methotrexate, vinblastine,
doxorubicin, and cisplatin (MVAC) or gemcitabine plus cisplatin [18]. Using drug combinations
not only fixes resistance problems but also improves the response rate of patients. For example,
MVAC overall response rate is 39%, while cisplatin alone has only a 12% overall response rate
in bladder cancer patients [77]. In study of gemcitabine and cisplatin combination, patients’
overall survival was observed to be longer when comparing the combination to single drug
treatment, as overall survival length of gemcitabine plus cisplatin’s patients is at 8 months,
compared to 6 months when treated with gemcitabine alone in pancreatic cancer patients [78].
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In a combination therapy that has a synergistic effect, each drug can be used with more
effective outcomes and lessen life-threatening toxicity. For example, a combination of 1,250
mg/m2 of capecitabine and 75 mg/m2 of docetaxel has a higher efficacy in time to disease
progression, overall survival, and objective tumor response rate than 100 mg/m2 of docetaxel
alone. The combination also has a lower life-threatening level of toxicity than single therapy at
25% vs 30%, respectively. However, some less severe side effects are more common in patients
treated with capecitabine/docetaxel combination than docetaxel monotherapy [79].
Some drugs can be repurposed to be used as a combination. For example, romidepsin is
an approved anti-cancer drug for T-cell lymphomas, but it is not as effective against solid tumors
when used alone [80]. However, the combination of romidepsin, cisplatin, and nivolumab has
been shown to be effective for solid cancer treatment [78]. Another example is a combination of
binimetinib and encorafenib. Binimetinib has been shown to suppress tumor where the ERK
pathway is overactive [81, 82]. Drug resistance often developed when using only Mek inhibitors
due to the feedback reactivation of the ERK pathway [81, 82]. When using a combination of
binimetinib and encorafenib, a B-Raf inhibitor, to target tumors that have an overactive ERK
pathway, the combination can effectively suppress tumor and prevent drug resistance [81, 82].
Thus, as supported by this evidence, using drug combinations could reduce drug
resistance, improve overall response, improve the survival rate of patients, and also can
repurposing existing drugs for treating various types of cancer. Therefore, it is necessary to come
up with novel and efficacious drug combinations. In this dissertation, I focused on formulating
the combination of gemcitabine, cisplatin, and romidepsin. I will provide more details about each
drug in the next section.
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1.7 Chemotherapeutic reagents for the formulation of the drug combination
Improving patients’ quality of life and mitigating side effects are treatment goals for any
type of cancer treatment. Chemotherapeutic agents have been used as first line therapy and
adjuvant therapy for many types of cancer. In this dissertation, I focus on using three
chemotherapeutic reagents: cisplatin, gemcitabine, and romidepsin to formulate a new
combination regimen.

1.7.1 Cisplatin
Cisplatin, or cis-diamminedichloroplatinum (II), is a platinum based anti-cancer agent
(see structure in Fig. 1.4). Cisplatin induces apoptosis by crosslinking purine bases in DNA. This
results in DNA damage and DNA repair interference [83–86].
A critical step in the molecular mechanism of cisplatin is the cellular uptake of the drug
so the drug can be transported to the nucleus in order to interact with DNA. Cellular export of
the drug is equally important, as the efflux of it has been shown to be one of the mechanisms that
lead to cisplatin resistance. Thus, proteins that control drug efflux, such as multi-drug resistanceassociated protein 2 (MRP2), can influence cisplatin resistance [87]. After transport into the
nucleus, cisplatin adducts with DNA at N7 of adenine and guanine [87]. This adduction induces
intra- and inter-strand crosslinks, which triggers a DNA damage response that leads to the
activation of cell cycle checkpoints Chk1 and Chk2. Cell cycle arrest may occur at G1, intra-S,
or G2 phase of the cell cycle before initiation of DNA repair. If the damage is beyond repair, the
cell will undergo apoptosis [85]. The MAPK pathway is involved in signaling transduction
following the detection of cisplatin-induced DNA damage [87]. Cisplatin also reportedly adducts
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with mitochondria and consequently induces ROS generation, which triggers apoptosis [86, 87].
ROS generation, due to cisplatin, can also damage the ER and induce protein misfolding, leading
to UPR-induced apoptosis [86].
Resistance to cisplatin limits its efficacy as an anticancer agent. Reduction of cisplatin
accumulation has been reported to be one of the features of cisplatin resistant cell lines. This is
caused by the upregulation of efflux regulation proteins such as MRP2. Accumulation of thiols is
another mechanism of cisplatin resistance as they are important detoxification molecules. Thiols
can bind to cisplatin and render the drug inactive [88]. Several cisplatin resistant cell lines have
been reported to have elevated concentrations of thiols, such as glutathione (GSH) or
metallothionein [88]. Another factor that contributed to cisplatin resistance is the ability of cells
to tolerate or repair DNA damage. Increased concentrations of nucleotide excision repair
proteins, such as ERCC1 and XPA are found to be associated with cisplatin resistance [88].
Nephrotoxicity has been reported as an adverse effect of cisplatin. 28-35% of patients
who receive an initial dose of 50-100 mg/m2 experience nephrotoxicity [86, 88]. However, high
volumes of fluid hydration and forced diuresis have been reported to prevent renal damage [85,
87]. Vomiting and hepatotoxicity are also observed [74, 75]. Toxicity is the result of the
accumulation of the drug at a non-cancerous site.
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Figure 1.4 Chemical structure of cisplatin
(Adapts from Wikipedia, commons.wikimedia.org)

1.7.2 Gemcitabine
Gemcitabine (2’,2’-difluorodeoxycytidine, dFdC), or also known as Gemzar (see
structure in Fig. 1.5) is a nucleoside analog. Gemcitabine is the standard first-line treatment of
pancreatic adenocarcinoma. In addition, gemcitabine is often used as a single agent to treat nonsmall cell lung cancer and is combined with other drugs for the treatment of breast cancer and
bladder cancer [89-95].
Gemcitabine has many mechanisms of action. The main mechanism of gemcitabine is to
inhibit DNA synthesis. Gemcitabine is transported into cells by concentrative nucleoside
transport (CNT) or by an equilibrative nucleoside transporter (ENT). Once transported to the
cytosol, gemcitabine is activated by deoxycytidine kinase (dCK) by phosphorylation to mono-,
di-, and gemcitabine triphosphate (dFdCTP). Altered dCK activities have been reported to be a
source of gemcitabine resistance. Phosphorylated gemcitabine then incorporates into DNA.
Incorporation of dFdCTP causes DNA polymerization to stop, resulting in single-strand DNA
damage. dFdCTP is also incorporated into RNA, which blocks RNA synthesis [77-79].
Gemcitabine that has been incorporated into DNA can be recognized by the DNA-dependent
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kinase (DNA-PK) and the p53 complex. This complex binds to gemcitabine containing DNA and
triggers apoptosis [96].
Metabolites of gemcitabine inhibit enzymes involved in DNA synthesis, repair, and
salvage of (deoxy)ribonucleotides. Imbalance in the (deoxy)ribonucleotide pool, caused by the
inhibition of enzymes involved, leads to apoptosis. Gemcitabine also induces a G1/S-phase arrest
and triggers apoptosis in human leukemia and solid tumor cells [96]. Gemcitabine was found to
induce apoptosis through the MAPK pathway in human pancreatic cancer cells [96].
Gemcitabine also induces apoptosis through damaging mitochondria [96].
Gemcitabine resistance can be acquired by cancer cells through a reduction of proteins
involved in nucleoside metabolism, such as ribonucleotide reductase subunit I and II (RRM1,
RRM2), Human equilibrative nucleoside transporter 1 (hENT1), Human concentrative
nucleoside transporter 1 (hCNT1) and deoxycytidine kinase (dCK) [92, 96].
The most favorable outcome of gemcitabine is achieved when patients are treated with
800-1200 mg/m2 for 2-3 weeks followed by 1 week of rest [92]. However, myelotoxicity has
been the dose limiting factor for this schedule [92]. Side effects of gemcitabine are usually mild.
Common side effects of gemcitabine are mild-hematotoxicity, hepatotoxicity, nausea, vomiting,
and flu-like symptoms [97, 98].
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Figure 1.5 Chemical structure of gemcitabine
(Adapts from Wikipedia: commons.wikimedia.org)

1.7.3 Romidepsin
Romidepsin (also known as isodax, or FK228) is a histone deacetylase inhibitor (HDACi)
that was approved by the FDA for T-cell lymphoma treatment (see structure in Fig. 1.6). The
modification of histones is an important mechanism of gene regulation. Acetylation by histone
acetyltransferase (HAT) causes chromosomes to loosen, while deacetylation by histone
deacetylase (HDAC) causes chromosomes to tighten. The balance of acetylation/deacetylation is
required for cells to survive. Interfering with this balance could lead to cell death [99]. Dawson
and Kouzarides proposed a theory that cancer cells are more vulnerable to epigenetic
interference due to the difference in epigenetic regulation compared to non-cancerous cells [99].
Therefore, Histone deacetylase inhibitors are suited for cancer treatment.
Romidepsin, in combination with other therapeutic agents, can be used to treat breast
cancer effectively [100–104]. Romidepsin specifically targets HDAC class I. Like other HDACi,
romidepsin induces apoptosis by targeting epigenetic regulation [100, 101].
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Previous studies have shown that romidepsin selectively induces apoptosis in bladder
cancer cell lines expressing oncogenic H-Ras through the activation of the MAPK pathway. This
consequently enhances Nox-1 protein levels and increases ROS production, which leads to
apoptosis [47-51]. Romidepsin is also shown to enhance ROS accumulation in the cell by
reducing the levels of the ROS scavenger, GSH [50, 52]. Cell lines expressing multidrug
resistance-associated protein-1 (MRP1) have been shown to be resistant to romidepsin [104].
Romidepsin is given on days 1, 8, and 15 of a 28-day cycle of treatment [105]. Adverse
effects of romidepsin include gastrointestinal toxicities, such as diarrhea, nausea, vomiting, other
toxicities are thrombocytopenia, neutropenia, and fatigue [105]. In addition, patients were
reported to have experienced reversible ageusia (loss of taste) after treated with romidepsin
[106].

Figure 1.6 Chemical structure of romidepsin
(Adapts from Wikipedia, commons.wikimedia.org)
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1.7.4 Gemcitabine, romidepsin, and cisplatin in combination therapy
To formulate an effective combination treatment, drugs in the combination should have
varying mechanisms of action to target multiple pathways at the same time. Gemcitabine targets
DNA synthesis, while cisplatin causes DNA damage and inhibits DNA repair, and romidepsin
inhibits histone deacetylations. These three drugs attack cancer cells at different angles thus they
have the potential to work together as a combination. Cisplatin reportedly had nephrotoxicity
[86, 88], but nephrotoxicity is not an issue for gemcitabine and romidepsin [97, 98, 105, 106].
Thus, a combination of the three drugs with a lower dosage of cisplatin could reduce this type of
toxicity.
Gemcitabine is a drug that is often used in combination with other drugs since it has mild
toxicity and has multiple mechanisms of action [97, 98]. Cisplatin treated patients often
experience a relapse of cisplatin-resistant tumors. Hence, cisplatin is often used in combination
with other drugs to overcome recurrence and drug resistance [107]. The combination of
Gemcitabine and Cisplatin (GC) has been proven effective in controlling bladder cancer, nonsmall cell lung cancer, liver cancer, and bile duct cancer [108–110]. Using GC in combination
increases gemcitabine incorporation into DNA and increases cisplatin-DNA adducts [96,
111,112]. The synergy of tumor inhibition is possibly from the inhibition of the enzyme involved
in repairing cisplatin-DNA adducts, as DNA repair plays an important role in cisplatin induced
cell death [112]. Preclinical studies show that GC combination has additive and synergistic
effects. Although there is no clear evidence indicating the most effective administration
schedule, giving gemcitabine prior to cisplatin was shown to be synergistic, while the reverse
schedule produces an additive effect [97]. The study of using gemcitabine alone vs GC in
pancreatic cancer shows that the overall survival rate of GC is significantly higher than using
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gemcitabine alone (10 months vs 6 months, respectively) [78]. From the provided evidence,
combination gemcitabine and cisplatin have been proven to be synergistically effective in tumor
control for many types of cancer [96, 111, 112].
HDAC inhibitors are known for their ability to enhance the anticancer activity of other
chemotherapeutic agents [113]. The combination of romidepsin and cisplatin has been shown to
synergistically and preferentially induce cell death in breast and ovarian cancer cells [52, 114]
and to reduce cisplatin resistance of breast cancer cells [52]. Currently, the combination of
romidepsin, cisplatin, and the PD-1 inhibitor nivolumab is under phase II trial for treating breast
cancer [115]. This indicates that romidepsin could work with cisplatin synergistically.
Since romidepsin synergistically works with cisplatin in inducing tumor cell death while
reducing cisplatin resistance in breast cancer [18], combining romidepsin with GC could
potentially enhance anti-tumor properties through the ability of romidepsin to induce ROS
production and decrease GSH level. According to the mentioned evidence, I hypothesized that
these three drugs are suitable to be used as a combination and could work synergistically in
controlling tumor development.

1.8 Hypothesis and objective of the study
As mentioned, cancer is a resilient disease that kills millions of people in the United
States. Thus, better treatment for controlling cancer development and recurrence is needed to
combat this disease and improve patients’ quality of life. In this dissertation, I hypothesized that
the triple combination of gemcitabine plus romidepsin and cisplatin (Gem plus Rom+Cis) is
synergistically more effective at controlling cancer growth than either the double combination of
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gemcitabine and cisplatin or romidepsin and cisplatin, and is more effective than monotherapy of
gemcitabine, cisplatin, or romidepsin.
Working toward this hypothesis, the study is divided into these broad objectives:
-

To formulate the non-toxic combination of gemcitabine, cisplatin, and romidepsin for
cancer treatment for in vivo models.

-

To determine if the triple combination is better at inducing cancer cell death than double
combination and monotherapy.

-

To determine whether the triple combination can control drug resistant cancer.

-

To study the potential molecular mechanism for how the triple combination controls
tumor development.

-

To determine if the triple combination is better at controlling tumor development in the
cell-derived xenograft (CDX) models.
To complete these objectives, breast cancer and bladder cancer were used as models.

Bladder and breast CDX models were established for in vivo studies. With this study, we hope
that the results could be translated into a clinical trial and could ultimately help reduce cancer
related death in human patients and improve their quality of life.
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Research described in this chapter is slightly modified version of an article that has been
accepted for publication in Cancer Chemotherapy and Pharmacology
Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to
efficaciously and safely control triple-negative breast cancer tumor development
By Pawat Pattarawat, Shelby Wallace, Bianca Pfisterer, Agricola Odoi, and Hwa-Chain Robert
Wang
Pawat Pattarawat’s contribution in the paper includes the following:
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) Writing and
editing

50

Abstract
Triple-negative breast cancer (TNBC) is an aggressive, lethal, and heterogeneous subtype
of breast cancers, tending to have lower 5-year survival rates than other BC subtypes in response
to conventional chemotherapies.
This study was to identify advanced regimens to effectively control TNBC tumor
development. I investigated the combination of the DNA synthesis inhibitor gemcitabine, the
DNA-damaging agent cisplatin, and the histone deacetylase inhibitor romidepsin to control a
variety of breast cells in vitro. I studied the toxicity of drug doses and administration schedules
to determine tolerable combination regimens in immune-deficient nude and -competent BALB/c
mice. Then the efficacy of tolerable regimens in controlling TNBC cell-derived xenograft
development in nude mice was studied. By reducing clinically equivalent doses of each agent in
combination, we formulated tolerable regimens in animals. I verified that the tolerable triple
combination gemcitabine plus romidepsin+cisplatin regimen is more efficacious than double
combination regimens in controlling xenograft tumor development in nude mice. A triple
combination of gemcitabine+romidepsin+cisplatin synergistically induced death of the TNBC
M.D. Anderson-Metastatic Breast cancer (MDA-MB)231 and MDA-MB468, as well as
Michigan Cancer Foundation (MCF)7, MCF10A, and MCF10A-Ras cells. Cell death induced by
gemcitabine+romidepsin+cisplatin was in a reactive oxygen species-dependent manner.
Considering the high costs for developing a new anticancer agent, the FDA-approved
drugs gemcitabine, romidepsin (under clinical trial for TNBC, approved for T-cell lymphoma),
and cisplatin were used to economically formulate an efficacious and safe combination regimen.
The highly efficacious gemcitabine plus romidepsin+cisplatin regimen should be poised for
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efficient translation into clinical trials, ultimately contributing to reduced mortality and improved
quality of life for TNBC patients.
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2.1 Introduction
Triple-negative breast cancer (TNBC) is aggressive, lethal, and heterogeneous [1–4].
TNBC is defined by the absence of the three major breast cancer (BC) biomarkers estrogen
receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [2–
4]. TNBC accounts for more than 15% of BC cases. The number of cases has been increasing
over the last 10 years in the United States, reaching 268,600 new cases in 2019 and an estimated
41,760 deaths in U.S. women [5, 6]. Conventional chemotherapeutic agents to treat TNBC
include DNA damaging agents (cisplatin), DNA synthesis inhibitors (gemcitabine),
topoisomerase inhibitors, and microtubule inhibitors [4, 6–8]. Although there are initially high
response rates with these agents, TNBC tends to have lower five-year survival rates (85%) than
other BC types (94-99%) [6], largely due to recurrence and metastasis [4–7]. Currently,
combinations of conventional agents are undergoing pre-clinical and clinical studies to improve
the efficacy of regimens. A double combination regimen of gemcitabine and cisplatin (Gem+Cis)
has been clinically investigated to treat metastatic BCs; however, the Gem+Cis regimen did not
appear to provide an advantage over single agents for metastatic BCs [9]. On the other hand, 20
years of targeted therapeutic studies have largely focused on inhibiting specific BC-associated
aberrant modulators to regain control of cancer cell growth [3, 8, 10]. Nevertheless, pre-clinical
and clinical studies have revealed that inhibiting an aberrant modulator may result in an atypical,
compensatory induction of other pathways (ex, inhibition of HER2 resulted in HER3 activation)
to rescue cancer cells, leading to cancer recurrence [11–14]. Thus, considering those concerns in
drug development, there is a critical need for advanced regimens to achieve effective control of
TNBC malignancy, recurrence, and metastasis in order to reduce patient mortality.
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My studies indicated that a combination of the histone deacetylase inhibitor romidepsin
(Rom) with Cis, Rom+Cis, synergistically induces apoptosis in a variety of human and mouse
cells, including human BC cells [15, 16]. This occurs through the activation of the ERK pathway
to induce reactivation oxygen species (ROS) and activate caspases [15, 16]. My studies also
revealed the ability of Rom to preferentially induce apoptosis of Ras-expressing cells versus
counterpart cells [17–22]. Rom is FDA-approved to treat T-cell lymphoma; however, due to its
toxicity, its value in treating solid tumors has yet to be determined [23–26]. The Rom+Cis
regimen is currently undergoing clinical trials for treating metastatic TNBC [27, 28]. Rom+Cis
also has potential to be combined with Immunotherapeutic drugs, as currently combination of
Rom+ Cis with PD-1 inhibitor nivolumab is currently under phase II clinical trial for metastatic
breast cancer treatment (28). My recent studies detected that the Rom+Cis regimen was not
highly efficacious in controlling TNBC cell-derived xenograft (CDX) tumors in animals. To
further my investigation and identify advanced regimens for TNBC, I continued to study triple
combination regimens for the effective control of TNBC CDX tumors in animals.
In this communication, I demonstrated that a combination of Gem, Rom, and Cis
(Gem+Rom+Cis) synergistically induced breast cell death in a ROS-dependent manner in vitro. I
also demonstrated a step-by-step approach to initially determine tolerable doses and drugadministering schedules of combination regimens in mice. Subsequently, I determined the
efficacy of triple vs. double combinations of Gem, Rom, and Cis in controlling MDA-MB231
CDX tumor development in mice.
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2.2 Materials and methods
2.2.1 Cell cultures and reagents
MCF10A (American Type Culture Collection, Rockville, MD, USA) and MCF10A-Ras
cells [17] were maintained in complete medium (1:1 mixture of Dulbecco's Modified Eagle
Medium (DMEM) and Ham's F12, supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL
insulin, 0.5 µg/mL hydrocortisol, 20 ng/mL epidermal growth factor, and 5% horse serum).
MCF7, MDA-MB231, and MDA-MB468 cells (American Type Culture Collection) were
maintained in DMEM and supplemented with 10% fetal bovine serum [29]. Cultures were
supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin in 5% CO2 at 37 °C and
routinely subcultured every 2 to 3 days. Stock aqueous solutions of gemcitabine, romidepsin,
cisplatin (MedKoo, Morrisville, NC, USA), and chloromethyl–dichlorodihydrofluorescein–
diacetate (CM–H2DCF–DA) (Invitrogen, Carlsbad, CA, USA) were prepared in Dimethyl
sulfoxide (DMSO) and diluted in a culture medium for assays. Stock aqueous solution of Nacetyl-l-cysteine (NAC) (Alexis, San Diego, CA, USA) were prepared in distilled water and
diluted in a culture media for assays [16].

2.2.2 Cell viability
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (Travigen, Gaithersburg, MD, USA)
was used to measure cell viability [18, 19]. Five × 103 cells were seeded into each well of 96well culture plates. After treatments, cells were incubated with a MTT reagent for 4 h, followed
by an incubation with a detergent reagent for 24 h. The reduced MTT reagent in cultures was
quantified with an ELISA reader (Bio-Tek, Winooski, VT, USA).
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2.2.3 Colony formation
Five × 103 cells were seeded in a culture dish for 24 h, cells were treated with anticancer
agents for 48 h, and cultures were then rinsed and replaced with fresh medium. Growing cell
colonies (>30 cells) in vehicle- and drug-treated cultures were identified and counted after 7 and
14 days, respectively [16].

2.2.4 ROS measurement
Cells were incubated with 5 μM CM–H2DCF–DA for 1 h to detect Reactive oxygen
species (ROS) levels by flow cytometry [18]; the mean DCF fluorescence intensity of 2 × 104
cells was quantified using Attune cytometric software (Applied Biosystem, Foster City, CA,
USA).

2.2.5 Caspase activity
Caspase-3/7 activity was measured using a Caspase-Glo assay kit (Promega, Madison,
WI, USA). In brief, 30 μg of cell lysates were incubated with a caspase-3/7-specific
proluminescent substrate at ambient temperature for 1 h [18, 20]. The released luminescence was
measured in a luminometer plate reader (Bio-Tek).

2.2.6 Annexin-V apoptosis
An annexin-V-fluorescein isothiocyanate (FITC) apoptosis detection kit with propidium
iodide (BD Biosciences, San Jose, CA, USA) was used to detect apoptotic cell death by flow
cytometry [17, 18]. In brief, cells were collected after trypsinization, rinsed with Phosphate56

buffered saline (PBS), and incubated with annexin-V-FITC and propidium iodide for 20 min.
Flow cytometric analysis of annexin-V-FITC-labeled cells and propidium iodide-labeled cells
was performed with the Coulter EPICS Elite Cytometer (Hialeah, FL, USA) to determine the
percentage of cells undergoing apoptotic cell death using Multicycle software (Phoenix Flow,
San Diego, CA, USA).

2.2.7 Immunoblotting
Equal amounts of cellular proteins were resolved by electrophoresis in 10% SDS–
polyacrylamide gels and transferred to nitrocellulose filters for immunoblotting [21, 22], using
specific antibodies to detect poly(ADP-ribose) polymerase (PARP) (Cell Signaling, Danvers,
MA, USA) and β-actin (Santa Cruz, Santa Cruz, CA, USA). Antigen-antibody complexes on
filters were detected by the SuperSignal West Dura kit (Thermo Fisher, Rockford, IL, USA).

2.2.8 Animal Cell Line-Derived Xenograft (CDX) model
MDA-MB231 cells were mixed with Matrigel basement membrane matrix (BD
Biosciences) and inoculated subcutaneously into 5- to 6-week-old female athymic nu/nu (nude)
mice (Envigo, Indianapolis, IN, USA) to develop CDX tumors [30]. Tumor volume was
determined with a formula (length x width2 x ½) [31]. All animal procedures were approved by
the University of Tennessee Animal Care and Use Committee and were in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
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2.2.9 Histological examination
Isolated tissues were fixed in neutral-buffered formalin and embedded in paraffin,
followed by hematoxylin and eosin staining of tissue sections for histopathological examination.

2.2.10 Statistical analysis
A Student t test was used to analyze statistical significance, indicated by ∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.001; a p value of ⩽0.05 was considered significant. Combination indices analysis
was performed using the Chou and Talalay method [32] via the CompuSyn software suite
(ComboSyn, Paramus, NJ, USA). Combination indices less than, equal to, and greater than 1
indicate synergistic, additive, and antagonistic effects, respectively. Fisher’s extract test method
was used for analyzing the relationship between weight loss and death of animals. Survival
function was estimated by using the Kaplan-Meier method. The log-rank test method was used
for analyzing the equality of survival function.
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2.3 Results
2.3.1 Synergistic induction of cell death by Gem, Rom, and Cis
Extending from the previous study of the double combination Rom+Cis in controlling
BC cells [16], I investigated the ability of a triple combination of Gem and Rom+Cis
(Gem+Rom+Cis) to control BC cells. I initially determined the doses of inhibitory concentration
(IC) for each agent on MCF10A, MCF10A-Ras, MCF7, MDA-MB231, and MDA-MB468 cells.
MCF10A is an immortalized, non-cancerous, and ER-negative breast epithelial cell line lacking
p16 and p14ARF [33, 34]. MCF10A-Ras is derived from the ectopic expression of the oncogenic
H-Ras(V12) gene in MCF10A cells [16, 17]. MCF7 is an ER-positive BC cell line [35]. The
TNBC MDA-MB231 cell line carries mutations of the K-Ras and p53 genes, and the TNBC
MDA-MB468 carries amplified EGFR and mutations of the p53 and PTEN genes [36, 37].
Subsequently, I used the estimated IC10 doses of Gem, Rom, and Cis for each cell line (Fig. 2.1a)
to determine the ability of combined regimens to induce cell death. As shown in Figure 2.1b,
Gem+Rom+Cis induced higher degrees of death (reduced cell viability) than double and single
regimens in both MCF10A and MCF10A-Ras cells. The calculation of the combination index
revealed that Gem+Rom+Cis synergistically induced MCF10A and MCF10A-Ras cell death
(Fig. 2.1c). Using a colony formation assay, I detected that Gem+Rom+Cis, each at their IC10
doses, was able to reduce MCF10A cell survival to 3% and completely suppress MCF10A-Ras
cell survival (Fig. 2.1d). I then studied the ability of Gem+Rom+Cis to induce the death of
MCF7, MDA-MB231, and MDA-MB468 cells. Similarly, Gem+Rom+Cis induced higher
degrees of cell death than double and single regimens (Fig 2.1e) and synergistically induced cell
death (Fig. 2.1f). The results indicated that Gem+Rom+Cis was able to synergistically induce
death in a variety of breast cells.
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Figure 2.1 Synergistic induction of cell death by triple combination of Gem, Rom, and Cis. (a) MCF10A,
MCF10A-Ras, MCF7, MDA-MB231, and MDA-MB468 cells were treated with Gem, Rom, or Cis at various
concentrations for 48 h, and then cell viability was determined and normalized by the value determined in untreated
counterpart cells, as 100%. IC10 values of Gem, Rom, and Cis were estimated. (b and c) MCF10A and MCF10ARas cells were treated with Gem, Rom and/or Cis for 48 h, cell viability was determined (b), and combination effect
were calculated (c). (d) MCF10A and MCF10A-Ras cells were treated with Gem, Rom and/or Cis for 48 h, and
cultures were then replaced with fresh medium. Untreated cultures and treated cultures were stained with crystal
violet (0.5% w/v) on day 7 and 14, respectively. Cell colonies were counted, and relative colony formation was
normalized by the value determined in untreated cells, set as 100%. (e and f) MCF7, MDA-MB231, and MDAMB468 cells were treated with Gem, Rom, and/or Cis for 48 h, cell viability was determined (e), and combined
effects of combined agents on the cell viability were calculated (f). Combination indices less than 1 indicate
synergistic effects
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Figure 2.1 (continued)
.
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2.3.2 ROS-dependent cell death induced by Gem+Rom+Cis
Studying the mechanisms involved in Gem+Rom+Cis-induced cell death, I detected the
ability of Gem+Rom+Cis to induce ROS elevation (Fig. 2.2a), activate the apoptosis executioner
caspase 3/7 (Fig. 2.2b), and induce proteolysis of the caspase substrate poly(ADP-ribose)
polymerase (PARP) (Fig. 2.2c). Using NAC to block ROS, I detected that ROS was essential for
Gem+Rom+Cis-induced cell death (Fig. 2.2d). The blockage of ROS by NAC (Fig. 2.2a) also
significantly suppressed Gem+Rom+Cis-induced caspase activation (Fig 2.2b), PARP
proteolysis (Fig. 2.2c), and apoptotic-like cell death (Fig. 2.2e). The results indicated that
Gem+Rom+Cis was able to induce synergistic apoptosis of MDA-MB231 cells, and ROS
elevation played an essential role in the Gem+Rom+Cis-induced apoptosis.
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Figure 2.2 Gem+Rom+Cis regimen induced ROS-dependent apoptosis. MDA-MB231 cells were treated with
Gem+Rom+Cis in the absence and presence of the ROS blocker NAC for 48 h. (a) Cultures were labeled with CMH2DCF-DA for flow cytometric analysis of ROS levels. Relative fluorescence intensity, as fold induction (X,
arbitrary unit), was normalized by the fluorescence intensity determined in untreated, counterpart cultures, set as 1.
(b) Caspase-3/7 activity (X, arbitrary unit) in treated cultures was measured and normalized by the value determined
in the untreated counterpart cultures, set as 1. (c) Cell lysates were analyzed with immunoblotting to detect levels of
PARP and cleaved PARP with β-actin as a control. (d) Cell viability was measured. (e) Apoptotic-like cell death
was measured. Columns, mean of triplicates; bars, SD. The Student t test was used to analyze statistical significance,
indicated by *p < 0.05, **p < 0.01, ***p < 0.001. All results are representative of three independent
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2.3.3 Identification of tolerable combination regimens in vivo
To formulate a clinically applicable and safe regimen for Gem+Rom+Cis, I investigated
doses and administration schedules of Gem, Rom, and Cis individually and in combination in
animals. In treating TNBC and other cancer patients, 1,000 to 1,250 mg/m2 Gem is given at days
1 & 8, and 70 or 75 mg/m2 Cis is given at day 1 or 2 [38, 39]. In treating lymphoma patients, 8 to
17.5 mg/m2 Rom is given at days 1, 8, & 15 [23, 25]. Based on NCI’s Equivalent Surface Area
Dosage Conversion Factors [40], administering 1000 mg/m2 Gem, 15 mg/m2 Rom, and 70
mg/m2 Cis into humans is equivalent to administering 324 mg/kg gemcitabine, 5 mg/kg Rom,
and 23 mg/kg Cis into mice. Considering the synergy of Gem+Rom+Cis, the dose of each agent
was reduced to less than 25% in combination: 80 mg/kg Gem (80G), 1 mg/kg Rom (1R), and 5
mg/kg Cis (5C) for studying overlapped toxicity in mice.
Animal body weight loss is used as a parameter to determine the toxicity of drug
treatment in mice [41, 42]. I observed that body weight loss was an adverse side effect closely
associated with the toxicity of Gem, Rom, and Cis. Administering 80G, 40G, 20G, 1R, 20C, or
5C individually for 5 times did not result in body weight loss or other symptoms, such as the
inability to move, inability to eat or drink, respiratory distress, tremors, etc. (not shown).
However, administering the double combination regimens 80G plus 20C or 40G plus 20C for 2
consecutive cycles induced significant body weight loss (Fig. 2.3a). Adding 1-day of intervals
after the 2nd, 3rd, and 4th cycles alleviated body weight loss induced by the 40G plus 20C, but
not the 80G plus 20C. Five cycles of administering the 20G plus 5C or the 1R+5C regimen did
not cause animal body weight loss. Accordingly, the double combination of 80G plus 20C was
an intolerable, toxic regimen. The 40G plus 20C regimen reached the maximum tolerable dose
(MTD). The 20G plus 5C and the 1R+5C regimens were tolerable to nude mice.

64

I then combined Gem with Rom+Cis to result in the 20G plus 1R+5C. Administering
20G plus 1R+5C for 2 consecutive cycles induced body weight loss, and animals did not survive
after the third cycle of drug administration (Fig. 2.3b). Using Fisher’s extract test method, the
results revealed a statistically significant association of body weight loss with mortality (p <
0.001) and a significant difference between the treatment group and the control group (p < 0.05).
Adding 1-day of intervals after the 2nd, 3rd, and 4th cycles eliminated the drug-induced body
weight loss and enabled animals to survive. Interestingly, I detected that the toxic 20G plus
1R+5C regimen (without intervals) was tolerable in the immune-competent BALB/c mice (Fig
2.3c). Accordingly, the results indicated that the immune-competent BALB/c mouse strain
tolerated the 20G plus 1R+5C regimen more than the immune-deficient nude mice. The 20G plus
1R+5C regimen without an interval was intolerable and toxic to nude mice. The 20G plus
1R+5C regimen with 1-day intervals after the 2nd, 3rd, and 4th cycle of treatment became
tolerable in mice. The tolerable 20G plus 1R+5C regimen contained reduced doses of Gem,
Rom, and Cis to less than 6%, 25%, and 25%, respectively, of their clinically equivalent doses.
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Figure 2.3 Identification of tolerable doses and drug administering schedules for the triple combination
Gem+Rom+Cis regimen in vivo. The immuno-deficient nu/nu (nude) or the immuno-competent BALB/c were
injected (i.p.) with 80, 40, or 20 mg/kg Gem (80G, 40G, or 20G), 1 mg/kg Rom (1R), and/or 20 or 5 mg/kg Cis (20C
or 5C) at indicated days as scheduled with 0, 1, or 2 days of interval. Body weight was measured every 2 days to
determine the intolerable and tolerable adverse side effects of a regimen on animals. (a) Nude mice were
administered with double combinations of 80G plus 20C, 40G plus 20C, 20G plus 5C, or 1R+5C. (b) Nude mice
were administered with the triple combination of 20G plus 1R+5C at two schedules with or without intervals. (c)
BALB/c mice were administered with the triple combination of 20G plus 1R+5C for 5 times without an interval.
Animals detected with 20% body weight loss of the original body weight (day 1), indicating an intolerable adverse
side effect, were removed to terminate the study. The regimen induced the intolerable adverse side effect was
determined as a toxic (tox) regimen.
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Figure 2.3 (continued)
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2.3.4 Histological examination and blood analysis of toxicity
Liver and kidney problems and myelosuppression are reportedly the main adverse side
effects associated with Gem, Rom, and Cis [24, 25, 43, 44]. I isolated livers, kidneys and bone
marrows from nude mice administered with the tolerable and intolerable regimens of 20G plus
1R+5C and PBS. Histopathological examination did not reveal any toxic lesions in the kidney of
control or treated mice (Fig 2.4a). Minor periportal inflammation and infiltrates of lymphocytes
surrounding portal triad in the livers were detected in mice administered with the toxic 20G plus
1R+5C regimen, but not in the control or non-toxic regimen-treated mice. Decreased overall
cellularity with dilations of bone marrow sinuses filled with mature erythrocytes (bone marrow
angiectasis) was detected in mice treated with the toxic 20G plus 1R+5C regimen but not the
non-toxic regimen. Bone marrow angiectasis is associated with severe hematopoietic tissue loss,
inflammation, neoplasia, or other processes [45, 46]. Furthermore, while investigating the
adverse effects related to myelosuppression, I isolated blood from mice administered 5 cycles of
PBS or the tolerable 1R+5C, 20G plus 5C, and 20G plus 1R+5C regimens with one-day intervals
(Fig 2.4b). Blood analysis did not reveal any significant changes in white blood cells,
hemoglobin, and platelet in animals treated with tolerable regimens.
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Figure 2.4 Toxicity of Gem+Rom+Cis regimens on mice. (a) Nude mice were administered with PBS or the toxic
20G plus 1R+5C regimen for 3 cycles. Histological examination of the kidney, liver, and bone marrow of mice
administered with the 20G plus 1R+5C tox. Lesion was not detectable in the kidney. Periportal inflammation and
minor infiltration of lymphocytes to portal triad were detectable (boxed area) in the liver. Loss of hematopoietic
tissue was detectable with decreased overall cellularity and moderate dilations of bone marrow sinuses filled with
mature erythrocytes (boxed area) in the bone marrow. (b) Nude mice were administered with PBS, 1R+5C, 20G
plus 5C, or 20G plus 1R+5C for 5 cycles. Blood was collected for analysis to reveal any changes in WBC, HGB,
and PLT. Results were presented in mean ± SD.
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2.3.5 Efficacy of Gem plus Rom+Cis in controlling CDX tumor development
MDA-MB231 cells were inoculated subcutaneously into the mammary fat pad area of
nude mice. Mice developing CDX tumors reaching~15 mm3 were admitted into the study. Mice
in the control cohort 1 were administered (i.p.) PBS. Cohorts 2, 3, and 4 were administered the
1R+5C, 20G plus 5C, and the tolerable 20G plus 1R+5C regimens, respectively, for 5 cycles.
Analysis of tumor volume revealed that two cycles of treatment with these regimens effectively
controlled tumor growth (Fig 2.5a). However, tumors appeared to become resistant to the 1R+5C
regimen after 3 cycles. The 20G plus 5C and the 20G plus 1R+5C regimens were efficacious in
controlling tumor development throughout treatment cycles; however, tumors appeared to recur
in mice after 5 cycles of treatment with the 20G plus 5C regimen. Analysis of final tumor
volume revealed an increase of tumors to 300% in vehicle-treated mice, and tumors doubled
their volume in mice treated with the 1R+5C regimen (Fig 2.5b, 2.5c). Tumors reduced to ~64
and ~27% of their original volume in mice treated with the 20G plus 5C regimen and the 20G
plus 1R+5C regimen, respectively. Measuring tumor weight reflected the ability of these
regimens to control tumor development (Fig 2.5b, T/C ratio). Histological examination revealed
that ~0.6 and ~2.8 mitotic figures per 400x fields in tumor tissues isolated from mice treated with
20G plus 1R+5C and control mice, respectively (Fig. 2.5d). Individual cell death was also
detectably higher in tumors isolated from mice treated with 20G plus 1R+5C than in mice treated
with vehicle at an average of 2.6 vs. 1.6 individual cell death per field, respectively. The results
indicated that 20G plus 1R+5C regimen induced growth inhibition and death of tumor cells. The
efficacy of these combination regimens in controlling tumor development are as follows: 20G
plus 1R+5C > 20G plus 5C > 1R+5C. The 20G plus 1R+5C regimen appeared to be more
efficacious than the 20G plus 5C regimen in controlling tumor recurrence.
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Figure 2.5 Efficacy of non-toxic regimen in the control of xenograft tumor development. Five x 106 MDAMB231 cells were mixed with Matrigel and inoculated into mammary fat pad areas of nude mice. Tumor volume
was determined with a formula (length x width2 x ½) [31]. (a) Mice developing xenograft tumors reaching ~15 mm3
were entered into studies (day 1). Mice (cohort 1, control) were injected (i.p.) with PBS, cohort 2 (R+C) were
injected with 1R+5C 5 times (at days 2, 4, 7, 10, &13), cohort 3 (G plus C) were injected with 20G 5 times (at days
1, 3, 6, 9, & 12) and 5C 5 times (at days 2, 4, 7, 10, & 13), and cohort 4 (G plus R+C) were injected with 20G 5
times (at days 1, 3, 6, 9, & 12) and 1R+5C 5 times (at days 2, 4, 7, 10, & 13). Tumor volume was recorded; volume,
mean ± SE. Mice were histo-pathologically examined during necropsy at day 16. (b) Changes of tumor volume (%)
were calculated by T16 (tumor volume determined at day 16)/T1 (tumor volume determined at day 1). Average
weight of tumors isolated at day 16 was measured, mean ± SE. Final tumor/control ratio (T/C) was calculated by T
(mean tumor weight of treatment group)/C (mean tumor weight of control group) of tumors isolated from mice at
day 16. *p < 0.05, ***p < 0.001. (c) Representative tumors were shown. (d) Tumors isolated from control mice and
mice treated with G plus R+C were histologically examined. White arrows indicate mitosis, and black arrows
indicate cell death. An average of 2.8 and 0.6 mitotic figures per 400x field was detected in tumors isolated from the
control and G plus R+C-treated mice, respectively. An average of 1.6 and 2.6 cell death per 400x field was detected
in tumors isolated from the control and the G plus R+C-treated mice, respectively.
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Figure 2.5 (continued)
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2.4 Discussion
For the first time, my studies demonstrated that a triple combination of Gem, Rom, and
Cis is safe and highly efficacious in the control of TNBC CDX tumor development. Efficacy,
safety, and affordability are major criteria for drug development. To maximize the efficacy of
combination regimens to control cancers, it is equally important to minimize the overlapping
toxicity of combined agents. My in vitro studies reveal a synergy of combining Gem, Rom, and
Cis to induce death of the TNBC MDA-MB231 and MDA-MB468 cells in addition to noncancerous breast epithelial MCF10A and cancerous MCF10A-Ras and MCF7 cells. Considering
the synergy of Gem+Rom+Cis, I formulated regimens with reduced doses of each agent in
combination to reduce overlapped toxicity in the animal studies.
Prior to studying the efficacy of Gem+Rom+Cis in controlling tumor development, I
investigated the drug-related, dose-limiting adverse effects, where I observed that body weight
loss was a closely associated adverse side effect with the toxicity of Gem+Rom+Cis in mice.
Although the nude mouse was a congenic strain of the BALB/c mouse, the nude strain was less
tolerable than BALB/c strain to Gem+Rom+Cis, possibly due to the mutated genes involved in
making the immune-deficiency. Histological examination revealed lesions in the livers and
hematopoietic tissue loss with a decrease cellularity in the bone marrows of mice treated with the
toxic 20G plus 1R+5C regimen but not with the non-toxic regimen with one-day intervals. Blood
analysis also did not reflect any changes induced by the non-toxic 20G plus 1R+5C regimen. The
20G plus 1R+5C regimen without any intervals was toxic, causing liver damages and
myelosuppression in nude mice. Inserting one-day intervals into the drug administration schedule
after the 2nd, 3rd, and 4th cycle reduced the toxicity of the 20G plus 1R+5C regimen to result in
a non-toxic, tolerable, and safe regimen.
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The non-toxic triple combination 20G plus 1R+5C regimen was highly efficacious in
controlling MDA-MB231 CDX tumor development. The non-toxic 20G plus 1R+5C regimen
was more efficacious than the 20G plus 5C, and the 20G plus 5C was more efficacious than the
1R+5C regimen in controlling tumor development in mice. The 20G plus 1R+5C regimen also
appeared to be more efficacious than the 20G plus 5C regimen in controlling tumor recurrence.
My in vitro data indicated that Gem+Rom+Cis was more effective than Gem+Cis, and Gem+Cis
was more effective than Rom+Cis in inducing MDA-MB231 cell death. The Gem+Rom+Cis was
able to induce ROS-dependent apoptotic-like cell death. My in vivo results appeared to correlate
with my in vitro data.
Histological examination supported that the 20G plus 1R+5C regimen was effective in
inducing growth inhibition and individual cell death of tumor tissues in animals. It is known that
Gem and Cis induce drug resistance through mechanisms, including induction of PARP-involved
DNA repair and ROS elevation for cell survival [14, 47]. The ability of Gem+Rom+Cis to
induce proteolysis of PARP and lethal levels of ROS conceivably helped suppress PARPinvolved DNA repair and survival-related ROS in Gem- and Cis-induced drug resistance,
resulting in turning the Gem+Cis-induced resistance into apoptosis. Thus, the combination of
Gem, Rom, and Cis may complementarily and cooperatively induce death and suppress
resistance in TNBC cells. TNBC is a molecularly heterogeneous subtype of BCs [1–4]. The
TNBC MDA-MB231 cell line carries mutations of the K-Ras and p53 genes, and MDA-MB468
carries mutations of the p53 and PTEN gene and amplified EGFR [36, 37]. The extent to which
other molecular subtypes of TNBC are susceptible to the Gem plus Rom+Cis regimen remains to
be determined.
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The tolerable 20G plus 1R+5C regimen contained reduced doses of Gem, Rom, and Cis
to less than 6%, 25%, and 25%, respectively, of their clinically equivalent doses. Analysis of the
results of toxicity and efficacy together, the administration of 20G plus 1R+5C for 2 cycles
followed by a 1-day interval and the insertion of 1-day interval between every following cycles
of drug administration effectively alleviated the cumulative toxicity, thereby converting a toxic
20G plus 1R+5C regimen into a non-toxic regimen without compromising its efficacy to control
the TNBC MDA-MB231 CDX tumor development.

2.5 Conclusion
Currently, the development of a single therapeutic drug may cost >$2 billion [48].
Considering the affordability of an advanced regimen for TNBC, I formulated an efficacious and
safe triple combination regimen consisting of Gem, Rom, and Cis, which are already FDAapproved anticancer agents. Thus, the regimen should be poised for efficient and economic
translation into clinical trials, ultimately contributing to reducing mortality and improving TNBC
patients’ quality of life.
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Chapter 3
Compensatory combination of romidepsin with gemcitabine and cisplatin to
effectively and safely control urothelial carcinoma
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Abstract
Human urothelial carcinoma (UC) has a high tendency to recur and progress to lifethreatening advanced diseases. Advanced therapeutic regimens are needed to control UC
development and recurrence.
I pursued in vitro and in vivo studies to understand the ability of a triple combination of
gemcitabine, romidepsin, and cisplatin (Gem+Rom+Cis) to modulate signaling pathways, cell
death, drug resistance, and tumor development.
My studies verified the ability of Gem+Rom+Cis to synergistically induce apoptotic cell
death and reduce drug resistance in various UC cells. The ERK pathway and reactive oxygen
species (ROS) played essential roles in mediating Gem+Rom+Cis-induced caspase activation,
DNA oxidation and damage, glutathione reduction, and unfolded protein response.
Gem+Rom+Cis preferentially induced death and reduced drug resistance in oncogenic H-Rasexpressing UC versus counterpart cells that was associated with transcriptomic profiles related to
ROS, cell death, and drug resistance. My studies also verified the efficacy and safety of the
Gem plus Rom+Cis regimen in controlling UC cell-derived xenograft tumor development and
resistance.
More than 80% of UCs are associated with aberrant Ras-ERK pathway. Thus, the
compensatory combination of Rom with Gem and Cis should be seriously considered as an
advanced regimen for treating advanced UCs, especially Ras-ERK-activated UCs.
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3.1 Introduction
Urothelial carcinomas (UCs) account for >90% of urinary bladder cancer cases, which
have been growing for the past 10 years in the US, reaching 80,470 new cases in 2019 and
resulting in approximately 17,670 deaths [1]. Conventional transurethral resection,
chemotherapy, and Bacillus Calmette-Guerin immunotherapy are effective short-term treatments
for UCs; however, >50% of UCs recur and progress to life threatening, advanced muscleinvasive UCs (MIUCs) [2-4]. Either a combination of gemcitabine (Gem) and cisplatin (Cis), the
Gem plus Cis regimen, or a combination of methotrexate, vinblastine, adriamycin, and cisplatin
(MVAC), are used as the standard treatment for advanced UCs [5, 6]. Because the Gem plus Cis
regimen is less toxic than the MVAC regimen, the Gem plus Cis regimen is currently the
preferred first-line chemotherapy for advanced UCs [5, 6]. Gem is a DNA synthesis-inhibiting
agent, and Cis is a platinum-based DNA-damaging agent [5, 6]. However, despite the initial high
response rates with these regimens, the overall 5-year survival rate of MIUC patients is less than
35% largely due to drug resistance and cancer recurrence [2-4, 7]. Gem resistance involves
ribonucleotide reductase-catalyzed DNA synthesis, activation of survival ERK (Raf-Mek-Erk)
pathway, unfolded protein responses (UPR), etc [3-5, 7, 8]. Cis resistance involves the induction
of glutathione (GSH)-dependent detoxification, poly(ADP-ribose) polymerase (PARP)-involved
DNA repair, etc [3, 7, 9]. Thus, advanced regimens are urgently needed to effectively control
advanced UC development and recurrence [10, 11].
My research revealed that a combination of romidepsin (Rom, FK228) and Cis
synergistically induces death and reduces drug resistance in UC cells via elevation of reactive
oxygen species (ROS) to activate caspases and deplete GSH [12]. Rom is a histone deacetylase
inhibitor approved by the U.S. Food and Drug Administration (FDA) to treat T cell lymphoma
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[13, 14]. However, the therapeutic value of Rom for solid tumors is still unclear [14, 15]. My
studies also revealed that Rom is preferential to induce apoptosis and reduce drug resistance in
oncogenic H-Ras-expressing cells versus counterpart cells, via elevation of ROS and induction
of the ERK pathway to activate caspases and deplete GSH [16-20]. Although Cis alone is
ineffective in inducing GSH depletion, Cis enhances the ability of Rom to deplete GSH [12].
Accordingly, the integration of Rom into the standard Gem plus Cis regimen, resulting in Gem
plus Rom+Cis, may advance therapeutics to effectively control UC development and recurrence.
In this communication, I demonstrated the ability of the triple combination Gem plus
Rom+Cis regimen to synergistically induce death and reduce drug resistance in various UC cell
lines in vitro. I investigated the mechanisms for Gem+Rom+Cis’s ability to control UC cells. I
also demonstrated in vivo studies to verify the efficacy of Gem plus Rom+Cis regimen in
controlling UC cell-derived xenograft (CDX) tumor development and resistance.
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3.2 Materials and methods
3.2.1 Cell cultures and reagents
Human UC J82, T24, SW780 (American Type Culture Collection, Rockville, MD, USA),
and oncogenic H-Ras(V12)-expressing J82-Ras cells were maintained in DMEM with 5% heatinactivated fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin [16]. The J82Ras cell line was established from the ectopic expression of the oncogenic H-Ras gene in J82
cells by constant transfection with pcDNA4/TO-E-H-ras plasmid [16]. Cultures were maintained
in 5% CO2 at 37 °C and subcultured every 2-3 days. Stock solutions of Rom, Cis, and Gem
(Medkoo, Chapel Hill, NC, USA), U0126 (Cell Signaling, Beverly, MA), chloromethyldichlorodihydrofluorescein-diacetate (CM-H2DCF-DA) (Invitrogen, Carlsbad, CA, USA), and
ML171 (EMD Millipore, Billerica, MA, USA) were prepared in DMSO. Stock solution of Nacetyl-L-cysteine (NAC) (Alexis, San Diego, CA, USA) were prepared in distilled water. Stock
solutions were diluted in culture medium for assays. Dosages of each reagent used in vitro or in
vivo assays are listed in Table 3-1 and Table 3-2, respectively.

Table 3-1 Concentrations of agents used in vitro studies.
Cell line
J82
J82-Ras
SW780
T24

Gemcitabine
(µM)
0.4
0.2
0.4
0.2

Romidepsin Cisplatin
(nM)
(µM)
1
3
0.5
3
0.7
10
0.4
3
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NAC
(mM)
5
5
5
5

U0126
(µM)
2.5
2.5
2.5
2.5

ML171
(µM)
1
1
1
1

Table 3-2 Treatment dosage and schedule for in vivo studies.
Regimen
Drug dosage
20
mg/kg
of
Gem
in PBS, IP
Gem plus
Cis
5 mg/kg of Cis in PBS, IP
Rom +Cis 1 mg/kg of Rom+ 5 mg/kg of Cis in PBS, IP
Gem plus 20 mg/kg of Gem in PBS, IP
Rom+Cis 1 mg/kg of Rom+ 5 mg/kg of Cis in PBS, IP
Gem: Gemcitabine; Rom: Romidepsin; Cis: Cisplatin

Schedule
Day 1, 3, 6, 9 & 12
Day 2, 4, 7, 10 & 13
Day 1, 3, 6, 9 & 12
Day 1, 3, 6, 9 & 12
Day 2, 4, 7, 10 & 13

J82 cells were constantly transfected with the pcDNA3.1+/human GRP78/BiP (binding
immunoglobulin protein) plasmid DNA (GenScrpit, Piscataway, NJ, USA) and the psinU6.1/GRP78-short hairpin loop RNA (shRNA) plasmid DNA (GeneCopoeia, Rockville, MD,
USA), using TurboFect transfection reagent (Thermo Fisher, Waltham, MA, USA), to generate
BiP-expressing J82 cell lines (J82-BiP-1 & J82-BiP-2) and BiP-downregulated J82 cell lines
(J82-shBiP-1 & J82-shBiP-2) after selection with 1000 μg/mL of G418 (Corning, Corning, NY,
USA) or 0.8 μg/mL of puromycin (Sigma-Aldrich, St. Louis, MO, USA), respectively. The
targeted sequences for J82-shBiP-1 and J82-shBiP-2 were GCCTGACACCTGAAGAAATCG
and GGAACCATCCCGTGGCATAAA, respectively.

3.2.2 Cell viability
Cultured cells were treated with anticancer agents for 48 h. A methyl thiazolyl
tetrazolium (MTT) assay kit (Travigen, Gaithersburg, MD, USA) was used to quantify cell
viability with an enzyme-linked immunosorbent assay plate reader (Bio-Tek, Winooski, VT,
USA) at 570 nm [12, 16-21]. Relative values of cell viability in treated cultures were normalized
by the value determined in untreated counterpart cells, set as 100%.
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3.2.3 Immunoblotting
Cells were treated for either 24 or 48 h, cell lysates were prepared, and protein
concentrations were measured using the BCA assay (Thermo, Rockford, IL, USA) [12, 16-21].
Equal amounts of cellular proteins were resolved by electrophoresis in 10% SDS–
polyacrylamide gels and transferred to nitrocellulose filters for immunoblotting, using specific
antibodies to detect Ras, phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, NADPH oxidase-1 (Nox-1),
β-actin (Santa Cruz, Santa Cruz, CA, USA), phosphorylated Mek1/2 (p-Mek1/2), Mek1/2, BiP,
and PARP (Cell Signaling). Concentrations of each antibody and blocking agent are shown in
the Table 3-3. Antigen-antibody complexes on filters were detected by the SuperSignal West
Dura kit (Thermo). Levels of specific phosphorylation of Mek1/2 (p-Mek1/2) and Erk1/2 (pErk1/2) were calculated by normalizing the levels of p-Mek1/2 and p-Erk1/2 with the levels of
Mek1/2 and Erk1/2, respectively, then the level set in control cells as 1 (X, arbitrary unit). Levels
of Ras, Nox-1, BiP, and PARP were calculated by normalizing with the level of β-actin and the
level set in control cells as 1 (X, arbitrary unit)
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Table 3-3 Specific antibodies used in immunoblotting.
Catalogue
Blocking
Dilution
number
solution
H-RAS
SCB
SC-520
1:500
5% NDM
MOX1 (Nox-1)
SCB
SC-518023
1:500
5% NDM
p-MEK kinase-1 SCB
SC-13020
1:1000
5% BSA
MEK kinase-1
SCB
SC-49449
1:1000
5% NDM
p-ERK
SCB
SC-7383
1:500
5% BSA
ERK-2
SCB
SC-154
1:1000
5% NDM
Actin
SCB
SC-1616
1:500
5% NDM
PARP
CST
9542S
1:1000
5% NDM
BiP
CST
3177S
1:1000
5% NDM
SCB: Santa Cruz Biotechnology; CST: Cell Signaling Technology, NDM: Nonfat dried milk;
BSA: Bovine serum albumin
Antibody

Company

3.2.4 ROS measurement
Cells were treated with anticancer agents for 48 h. Cells were then labeled with 5 µmol/L
CM-H2DCF-DA to measure ROS levels by flow cytometry using Multicycle software (Phoenix,
San Diego, CA, USA) [19-21]. The relative ROS level was measured and normalized by the
level determined in untreated counterpart cells, set as 1 (X).

3.2.5 Caspase activity assay
Cells were treated with anticancer agents for 24 h. Caspase-3/7 activity in cells was
measured using a Caspase-Glo assay kit (Promega, Madison, WI, USA) with a luminometer
plate reader (Bio-Tek) [12, 17-21]. The relative caspase-3/7 activity was determined and
normalized by cell viability, then the relative values were normalized by the value determined in
untreated counterpart cells, set as 1 (X).
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3.2.6 Annexin-V apoptosis assay
Cells were treated with anticancer agents for 24 h. An annexin-V-fluorescein
isothiocyanate (FITC) apoptosis detection kit with propidium iodide (BD, San Jose, CA, USA)
was used to measure the percentage of cells (%) undergoing apoptotic cell death by flow
cytometry using Multicycle software (Phoenix) [18,19].

3.2.7 Clonogenic assay
Triplicates of 5 × 103 cells were seeded in 60-mm culture dishes. Cultures were replaced
with fresh medium after treatments and maintained for 7 to 14 days [12, 16, 21]. Growing
colonies (> 30 cells) in untreated control cultures and drug-treated cultures were stained with
crystal violet (0.5% w/v) on days 7 and 14, respectively. Cell colonies were counted and
analyzed using TotalLab TL100 software (Newcastle, Tyne, UK, USA). Relative colony
formation was determined and normalized by the value determined in untreated counterpart cells,
set as 100%.

3.2.8 GSH measurement
Cells were treated with anticancer agents for 48 h. Intracellular GSH levels were then
measured with a QuantiChrom glutathione assay kit (BioAssay, Hayward, CA, USA) using GSH
disulfide as a standard [21]. Relative GSH level was normalized by the value determined in
untreated counterpart cells, set as 100%.
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3.2.9 DNA damage
DNA damage was detected with a comet assay [22], as preformed previously [21]. In
brief, after 24 h of treatment, 2 × 104 cells/mL in PBS were mixed with an equal volume of 1%
low-melting agarose (Fisher, Fair Lawn, NJ, USA) and placed on agarose-coated slides. Slides
were then lysed in an alkaline solution (1.2 M NaCl, 100 mM Na2EDTA, 0.26 M NaOH,
TritonX 100, pH 13) overnight at 4°C, electrophoresed in an alkaline buffer (0.3 M NaOH, 1
mM Na2-EDTA, pH > 13) at 20V/40 mA for 25 min, stained with propidium iodide, and
examined with a fluorescence microscope (Carl Zeiss, Thornwood, NY, USA). Fifty nuclei per
slide were scored for tail moment (% DNA in tail × tail length) using CometScore software
(Tritek, Sumerduck, VA, USA) [21]. The relative value of DNA damage was determined and
normalized by the value determined in untreated counterpart cells, set as 1 (X).

3.2.10 DNA oxidation
DNA oxidation was detected using a modified comet assay [23]. Briefly, after 24 h of
treatment, cells were seeded onto agarose-coated slides. Slides were immersed in lysis solution
(2.5 M NaCl, 0.1 M Na2-EDTA, and 10 mM Tris, pH 10) overnight at 4°C and then incubated
with a reaction buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM Na2-EDTA, and 0.2 mg/mL BSA,
pH 8) with and without formamidopyrimidine-DNA glycosylase (Fpg) for 30 min at 37°C.
Slides were then placed in an alkaline buffer (0.3 M NaOH, 1 mM Na2-EDTA, pH > 10),
electrophoresed, rinsed with a neutralization buffer (0.4 M Tris, pH 7.5), stained with propidium
iodide, examined with a fluorescence microscope, and analyzed with the CometScore software
(Tritek) [21, 23]. The relative value of DNA oxidation was determined and normalized by the
value determined in untreated counterpart cells, set as 1 (X).
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3.2.11 CDX model
Five to 6 weeks old, female immuno-deficient athymic nu/nu (nude) mice (Envigo,
Indianapolis, IN, USA) were used to establish CDX model. In brief, 2.5 x 106 J82-Ras or T24
cells were mixed with Matrigel basement membrane matrix (BD) and inoculated subcutaneously
into flank areas of each nude to develop CDXs [24]. Each cohort contained 4 mice calculated for
power analysis (at a power of 80%) in order to detect a difference in tumor size of 80 ± 20 mm3
in this pilot study. Isoflurane (3-5 %) (Zoetis, NJ, USA,) was used as an anesthesia by inhalation
during inoculation. Mice were housed in sterile cages in a temperature controlled room with 12 h
light-dark cycle at the University of Tennessee Laboratory Animal Facility. Mice were provided
with irradiated diet and water ad libitum. Animal were euthanized by CO2 exposure followed by
cervical dislocation. The dosage and schedule of treatment are listed in the Table 3-2. All animal
procedures were approved by the University of Tennessee Animal Care and Use Committee and
were in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

3.2.12 In Situ apoptosis detection
Paraffin embedded tumor tissues were deparaffinized and rehydrated, followed by using
the TACS 2 TdT-DAB In Situ Apoptosis Detection Kit (Trevigen, MD, USA) to detect apoptotic
cells. Cultures of J82-Ras cells were fixed with 3.7% formaldehyde and examined with the same
kit to detect apoptotic cells. Samples were counter stained by methyl green.
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3.2.13 Histological examination
Tumor tissues were isolated, fixed in neutral-buffered formalin, and embedded in
paraffin, followed by hematoxylin and eosin staining of tissue sections for histopathological
examination.

3.2.14 Transcriptomic analysis
Cellular RNAs were isolated with the Quick-RNA™ MicroPrep kit (Zymo, Irvine, CA,
USA) for transcriptomic analysis. The quality of RNAs was measured by an aglient bioanalyzer
2100 (Aglient, Santa Clara, CA, USA), and RNA samples with an RNA integrity number >7
were qualified for transcriptomic analysis. The Affymetrix GeneChip Human Transcriptome
Array 2.0A (>245,000 coding and >40,000 non-coding transcripts) and the Affymetrix
GeneChip® Scanner 3000 7G (ThermoFisher, Waltham, MA, USA) were used to detect gene
expressions. Data were analyzed using Python scripts to identify genes whose expression was
either significantly (FDR<0.05) increased or decreased by >2-fold. Custom gene ontology (GO)
[25] was used to analyze the functional enrichment of the modulated genes.

3.2.15 Statistical analysis
A Student t test was used to analyze statistical significance. The p values were adjusted
for multiple comparisons using the Simes method [26] with Stata 16 software (StataCorp LLC,
College Station, TX, USA). Statistical significance was indicated by *p < 0.05, **p < 0.01, ***p
< 0.001; a p value < 0.05 was considered significant. Combination indices analysis was
performed using the method by Chou and Talay [27] via the CompuSyn software suite (Paramus,
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NJ, USA). Combination indices <1, =1, and >1 indicate synergistic, additive, and antagonistic
effects, respectively.

3.3 Results
3.3.1 ROS- and ERK-Nox-dependent cell death synergistically induced by combined Rom,
Cis, and Gem
To investigate the ability of combined Gem with Rom and Cis in controlling UC cells, I
initially determined their inhibitory concentrations (ICs) for the UC J82 and the oncogenic HRas-expressing J82-Ras cells. Subsequently, I investigated the ability of combined agents at their
cognate IC10 doses (Table 3-1) to reduce J82 and J82-Ras cell viability (Fig. 3.1a-1). Using the
Chou-Talalay method [27], I determined that double and triple combinations of Rom, Cis, and
Gem synergistically reduced viability of J82 and J82-Ras cells (Fig. 3.1a-2), indicating that a
combination of these agents was able to synergistically induce UC cell death.
ROS elevation plays an important role in the cytotoxicity of Rom, Cis, and Gem [28-32].
Studying the ROS content in cells, I detected that treatment with these agents individually at
their cognate IC10 doses resulted in ROS elevation (Rom > Cis > Gem) (Fig. 3.1b). ROS were
increasingly induced by triple > double > single agents. ROS elevation has been shown to
correlate with oxidative lesions in DNA, DNA damage, and cell death [33]. I detected that DNA
oxidation was induced by Cis > Rom > Gem and induced by triple > double > single agents in
J82 and J82-Ras cells (Fig. 3.1c). Levels of DNA damage were closely correlated with levels of
DNA oxidation (Fig. 3.1d). Rom and Cis appeared to be more effective than Gem in inducing
DNA oxidation and DNA damage. Studying apoptosis-related pathways revealed that caspase3/7 activation was induced by Rom but not Cis and Gem at their IC10 doses in J82 cells. In
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contrast, caspase-3/7 was induced by Rom, Cis, and Gem in J82-Ras cells, and caspase-3/7 was
induced by triple > double > single agents (Fig. 3.1e). The triple combination induced cleavage
of PARP to a higher degree than single agent induced (Fig. 3.1f). Using NAC to block ROS
completely abrogated cell death, DNA oxidation, DNA damage, caspase-3/7 activation, and
PARP cleavage induced by Gem+Rom+Cis (Fig. 3.1a to 3.1f), indicating that Gem+Rom+Cis
induced cell death, DNA oxidation, DNA damage, caspase-3/7 activation, and PARP cleavage in
an ROS-dependent manner.
I showed that the ERK-Nox pathway is involved in ROS elevation and cell death induced
by Rom [19]. I also detected that double and triple combinations induced higher levels of
phosphorylated Mek1/2 and Erk1/2, as well as Nox-1 than single agents, indicating that double
and triple combinations induced higher activation of the ERK-Nox pathway than single agents
(Fig. 3.1g and Fig. 3.2). Co-treatment with NAC abrogated the activation of the ERK-Nox
pathway by Rom, Cis, and Gem, indicating that ROS elevation also played a role in ERK-Nox
pathway activation induced by Rom, Cis, and Gem.
To verify the role of the ERK-Nox pathway in cell death induced by Gem+Rom+Cis, I
used the Mek1/2 inhibitor U0126 to block the ERK pathway and the specific inhibitor ML171 to
suppress the Nox-1 activity in cells. Blockage of the ERK pathway resulted in suppressing
Gem+Rom+Cis-induced ROS elevation, caspase-3/7 activation, and cell death (Fig. 3.1h to
3.1j). Inhibition of Nox-1 by ML171 or overall ROS by NAC resulted in significant reduction of
Gem+Rom+Cis-induced ROS and apoptotic cell death (Fig. 3.1k & 3.1l). The results indicated
an important role the ERK-Nox pathway played in the induction of ROS elevation, caspase
activation, and apoptotic cell death induced by Gem+Rom+Cis.
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Figure 3.1 ROS- and ERK-Nox-dependent cell death synergistically induced by combined Rom, Cis, and
Gem. J82 and J82-Ras cells were treated with Rom, Cis, and/or Gem at their IC10 doses in the presence and absence
of NAC for 48 h (a & f) or 24 h (b, c, d, e, & g). (h to j) Cells were treated with Rom, Cis, and/or Gem in the
presence and absence of U0126 for 24 h (h and i) or 48 h (j). (k & l) Cells were treated with Gem+Rom+Cis in the
absence and presence of NAC or ML171 for 24 h (k) or 48 h (l). (a-1 & j) Cell viability was measured with an MTT
assay kit, and relative cell viability was normalized by the value determined in untreated counterpart cells, set as
100%. (a-2) Combined effects (a-1) were evaluated to reveal combination indices < 1 for synergistic effects. (b, h,
& k) Relative ROS levels were measured and normalized by the level determined in untreated counterpart cells, set
as 1 (X, arbitrary unit). (c) DNA oxidation was measured by an Fpg-modified comet assay and normalized by the
value of average tail moment determined in untreated control cells, set as 1 (X, arbitrary unit). (d) DNA damage was
measured by an alkaline comet assay and normalized by the value of average tail moment determined in untreated
control cells, set as 1 (X, arbitrary unit). Representative images of DNA oxidation and damage (c & d) are shown. (e
& i) Relative caspase-3/7 activity was determined and normalized by cell viability, and then the relative values were
normalized by the value determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (f & g) Cell lysates
were prepared and analyzed by immunoblotting using specific antibodies to detect levels of PARP, cleaved PARP,
p-Mek1/2, Mek1/2, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified by
densitometry. Levels of specific phosphorylation of Mek1/2 (p/Mek) and Erk1/2 (p/Erk) were calculated by
normalizing the levels of p-Mek1/2 and p-Erk1/2 with the levels of Mek1/2 and Erk1/2, respectively, then the level
set in control cells as 1 (X, arbitrary unit). Levels of Nox-1 (Nox/actin) were calculated by normalizing with the
level of β-actin and the level set in control cells as 1 (X, arbitrary unit). (l) Apoptotic cell population (%) was
measured by flow cytometry with an annexin-V-FITC apoptosis detection kit. Columns, mean of triplicates; bars,
SD. The p value was adjusted for multiple comparisons by using the Simes method. Statistical significance,
indicated by *p < 0.05, **p < 0.01, ***p < 0.001. All results are representative of three independent experiments.
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Figure 3.1 (continued)
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Figure 3.1 (continued)
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Figure 3.2 Densitometric analysis of Mek, Erk, and Nox levels. As performed in Fig. 3.1g, J82 and J82-Ras cells
were treated with Rom, Cis, and/or Gem at their IC10 doses for 24 h. Cell lysates were prepared and analyzed by
immunoblotting using specific antibodies to detect levels of phosphorylated Mek1/2 (p-Mek1/2), Mek1/2,
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified by
densitometry. Levels of specific phosphorylation of Mek1/2 (a, p-Mek/Mek) and Erk1/2 (b, p-Erk/Erk) were
calculated by normalizing the levels of p-Mek1/2 and p-Erk1/2 with the levels of Mek1/2 and Erk1/2, respectively,
then the level was set in untreated control cells as 1 (X, arbitrary unit). Levels of Nox-1 (c, Nox-1/actin) were
calculated by normalizing with the level of β-actin and the level set in control cells as 1 (X, arbitrary unit). Columns,
mean of triplicates; bars, SD. The p value was adjusted for multiple comparisons by using the Simes method.
Statistical significance, indicated by *p < 0.05, **p < 0.01, ***p < 0.001. All results are representative of three
independent experiments.
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3.3.2 Preferential induction of cell death and suppression of drug resistance by
Gem+Rom+Cis in J82-Ras vs. J82 cells
Studies showed the Rom preferentially induces death in J82-Ras vs. J82 cells [16-20]. To
reveal the ability of Gem+Rom+Cis to control J82-Ras vs. J82 cells, 0.5 nmol/L Rom (the IC10
dose for J82-Ras but non-cytotoxic to J82), 6 µmol/L Cis (the IC25 dose for both J82 and J82Ras), and 5 µmol/L Gem (IC25 dose for J82 but > IC25 for J82-Ras) were combined. Double or
triple combinations resulted in preferentially reducing viability of J82-Ras (ranging from ~50 to
~15%) vs. J82 (~65 to ~55%) cells, and the triple combination reduced viability of J82-Ras to
~15% vs. J82 to ~55% (Fig. 3.3a-1). Combination indices indicated that all the combinations
synergistically induced J82-Ras cell death. Rom+Cis and Rom+Gem synergistically induced J82
cell death, but Cis+Gem and Gem+Rom+Cis additively induced J82 cell death (Fig. 3.3a-2).
Also, Gem+Rom+Cis was more effective than single agents and double combinations in
preferential induction of ROS elevation, DNA oxidation, and DNA damage in J82-Ras vs. J82
cells (Fig. 3.3b to 3.3d). These results indicated that Gem+Rom+Cis was effective and
synergistic in preferentially inducing cell death, ROS elevation, DNA oxidation, and DNA
damage in J82-Ras vs. J82 cells.
Clonogenic survival rate serves as an index for drug resistance of cancer cells [34]. Drug
resistance to Cis for survival is associated with GSH-based detoxification [35, 36]. GSH is an
ROS scavenger, and depletion of GSH increases cellular susceptibility to ROS-induced apoptosis
[37]. I showed that although Cis by itself fails to reduce GSH, Cis enhances the ability of Rom to
reduce GSH in various cancer cells [12, 21]. Studying drug resistance, I detected that Rom and
Gem, but not Cis, preferentially reduced clonogenic survival in J82-Ras vs. J82 cells (Fig. 3.3e1). Rom+Cis and Rom+Gem reduced clonogenic survival of J82-Ras to ~10% and ~1% vs. J82
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cells to ~30% and ~5%, respectively, indicating that the two double combinations preferentially
reduced clonogenic survival of J82-Ras vs. J82 cells. However, Cis+Gem reduced clonogenic
survival of J82-Ras and J82 cells at a similar level (~1%). Gem+Rom+Cis was able to
completely suppress J82-Ras clonogenic survival to 0%, while minor survival (~1%) occurred in
J82 cells. Combination indices indicated that all the combinations synergistically reduced
clonogenic survival in J82 and J82-Ras cells (Fig. 3.3e-2). Accordingly, Gem+Rom+Cis was
more effective than single agents and double combinations to preferentially reduce drug
resistance in J82-Ras vs. J82 cells. The Gem+Rom+Cis was also more effective than single
agents and double combinations in the preferential reduction of GSH in J82-Ras vs. J82 cells
(Fig. 3.3f). Treatment with Rom or Gem, but not Cis, resulted in significantly reducing GSH;
and Gem appeared to reduce GSH to lower levels than Rom in both J82 and J82-Ras cells.
Although treatment with Cis reduced clonogenic survival (Fig. 3.3e-1), it did not reduce GSH in
either cells (Fig. 3.3f). Interestingly, combining Rom with Cis resulted in profoundly suppressing
clonogenic survival in J82 cells (Fig. 3.3e-1), but it did not reduce GSH (Fig. 3.3f). Blockage of
ROS with NAC effectively abrogated Gem+Rom+Cis-reduced GSH (Fig. 3.3g). These results
indicated that GSH depletion was involved in Gem+Rom+Cis-induced suppression of drug
resistance in J82 and J82-Ras cells in an ROS-dependent manner. Overall, ROS elevation, DNA
oxidation, DNA damage, and GSH depletion were relatively, but not fully, correlated with
induced cell death and reduced clonogenic survival by these agents, indicating other mechanisms
involved in the reduction of cell viability and drug resistance by Rom, Cis, and Gem remain to
be determined.
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Figure 3.3 Preferential induction of cell death and suppression of drug resistance by Gem+Rom+Cis in J82Ras vs. J82 cell. J82 and J82-Ras cells were treated with Rom, Cis, and/or Gem in the presence or absence NAC.
(a-1) Cell viability was measured with an MTT assay kit, and relative cell viability was normalized by the value
determined in untreated counterpart cells, set as 100%. (a-2) Combined effects (a-1) were determined to reveal
combination indices <1 or =1 for synergistic or additive effects, respectively. (b) Relative ROS levels were
measured and normalized by the level determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (c) DNA
oxidation was measured by an Fpg-modified comet assay and normalized by the value of average tail moment
determined in untreated control cells, set as 1 (X, arbitrary unit). (d) DNA damage was measured by an alkaline
comet assay and normalized by the value of average tail moment determined in untreated control cells, set as 1 (X,
arbitrary unit). (e-1) Clonogenic survival was measured by a clonogenic assay. Relative colony formation was
normalized by the value determined in untreated counterpart cells, set as 100%. (e-2) Combined effects (e-1) were
determined. (f & g) GSH content was determined, and relative GSH level was normalized by the value determined
in untreated counterpart cells, set as 100%. Columns, mean of triplicates; bars, SD. The p value was adjusted for
multiple comparisons by using the Simes method. Statistical significance, indicated by *p < 0.05, **p < 0.01, ***p
< 0.001. All results are representative of three independent experiments.
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Figure 3.3 (continued)
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3.3.3 Gem+Rom+Cis synergistically induced death and suppressed drug resistance in
SW780 cells
Clarifying whether the ability of the triple combination Gem+Rom+Cis to synergistically
induce death and reduce drug resistance was unlimited to the muscle-invasive UC J82 and J82Ras cells, I included the transitional cell carcinoma SW780 cell line in my studies. I determined
IC doses of Rom, Cis, and Gem for SW780 cells. I detected that Gem+Rom+Cis was more
effective than single and double agents to induce cell death, and all the combinations
synergistically induced death in SW780 cells (Fig. 3.4a-1 & 3.4a-2). Similar to J82 and J82-Ras
cells, treatment with Rom, Cis, and/or Gem induced the ERK-Nox pathway, ROS elevation,
caspase-3/7 activation, DNA oxidation, and DNA damage (Fig. 3.4b to 3.4f) that were relatively
increased by triple > double > single agents. The inhibition of ROS with NAC blocked
Gem+Rom+Cis-induced ERK-Nox pathway, caspase-3/7 activation, DNA oxidation, and DNA
damage. The inhibition of the ERK pathway with U0126 blocked Gem+Rom+Cis-induced pErk1/2, Nox-1, ROS, and caspase-3/7 (Fig. 3.4b to 3.4d). NAC blockage of ROS or ML171
inhibition of Nox-1 resulted in suppressing Gem+Rom+Cis-induced ROS and apoptotic cell
death (Fig.3.4g & 3.4h). These results indicated that ROS elevation was essential for
Gem+Rom+Cis-induced DNA oxidation and damage, and the ERK-Nox pathway and ROS were
mutually reliant and were both required for caspase-3/7 activation and apoptotic death induced
by Gem+Rom+Cis.
I also detected the ability of Gem+Rom+Cis, at their cognate IC10 doses, to completely
suppress clonogenic survival that was more effective than single and double agents (Fig. 3.4i).
GSH content was reduced by triple > double > single agents, and NAC inhibition of ROS
blocked Gem+Rom+Cis-induced GSH depletion (Fig. 3.4j), indicating an essential role of ROS
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elevation for GSH depletion. Although Cis was ineffective to induce GSH depletion (Fig. 3.4j),
it enhanced the ability of Rom and Gem to suppress clonogenic survival and deplete GSH (Fig.
3.4i & 3.4j). The results in SW780 cells were consistent with results from J82 and J82-Ras cells,
indicating that the ability of Gem+Rom+Cis to synergistically induce cell death and reduce drug
resistance was not limited to one type of UC cells.
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Figure 3.4 Gem+Rom+Cis synergistically induced death and suppressed drug resistance in SW780 cells.
SW780 cells were treated with Rom, Cis, and/or Gem at their IC 10 doses in the absence or presence of NAC, U0126,
or ML171. (a-1) Cell viability was determined, and relative cell viability was normalized by the value determined in
untreated counterpart cells, set as 100%. (a-2) Combined effects (a-1) were determined to reveal combination
indices <1 for synergistic effects. (b) Cell lysates were prepared and analyzed by immunoblotting using specific
antibodies to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified
by densitometry. Levels of specific phosphorylation of Erk1/2 (p/Erk) were calculated by normalizing the level of pErk1/2 with the level of Erk1/2, then the level set in control cells as 1 (X, arbitrary unit). Levels of Nox-1
(Nox/actin) were calculated by normalizing with the level of β-actin and the level set in control cells as 1 (X). (c &
g) Relative ROS levels were measured and normalized by the level determined in untreated counterpart cells, set as
1 (X). (d) Relative caspase-3/7 activity was determined and normalized by cell viability, and then the relative values
were normalized by the value determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (e) DNA
oxidation was measured by an Fpg-modified comet assay and normalized by the value of average tail moment
determined in untreated control cells, set as 1 (X). (f) DNA damage was measured by an alkaline comet assay and
normalized by the value of average tail moment determined in untreated control cells, set as 1 (X). (h) Apoptotic cell
population (%) was measured by flow cytometry with an annexin-V-FITC apoptosis detection kit. (i) Clonogenic
survival was measured by a clonogenic assay. Relative colony formation was normalized by the value determined in
untreated counterpart cells, set as 100%. (j) GSH content was determined and relative GSH level was normalized by
the value determined in untreated counterpart cells, set as 100%. Columns, mean of triplicates; bars, SD. The p value
was adjusted for multiple comparisons by using the Simes method. Statistical significance is indicated *p < 0.05,
**p < 0.01, ***p < 0.001. All results are representative of three independent experiments.
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Figure 3.4 (continued)
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3.3.4 Transcriptomic profiles associated with Gem+Rom+Cis
To detect molecular changes associated with the ability of Gem+Rom+Cis to modulate
ROS, cell death, and drug resistance, the Affymetrix GeneChip Human Transcriptome Array
2.0A was used, which carries more than 245,000 coding and 40,000 non-coding transcripts, to
detect gene expressions in cells. Initially, >25,000 coding transcripts were detected in J82-Ras
and J82 cells. Functional enrichment was quantified through GO analysis [25], which is based on
two lists of 2,087 and 3,720 annotated genes associated with ROS and cell death, respectively.
Because “drug resistance” is not a standard ontology term, a gene set from the database of
Genomic Elements Associated with drug Resistance (GEAR) was used [38], which provides a
list of 2,895 drug resistance-associated genes. Transcriptome analysis revealed 297 and 181
genes up- and down-regulated (> 2 folds, FDR < 0.05), respectively, by Gem+Rom+Cis in J82
cells; and 88 and 15 genes were up- and down-regulated, respectively, in J82-Ras cells (Fig.
3.5a). In J82-Ras cells, 13 ROS- and 22 cell death-associated genes were significantly upregulated by Gem+Rom+Cis, giving rise to significant enrichment of these two functions (Fig.
3.5b, p < 0.11, Fisher’s exact test). However, up-regulated drug resistant genes in
Gem+Rom+Cis-treated J82-Ras cells were not significantly enriched (p = 0.40, Fisher’s exact
test). In contrast, 50 drug resistance-associated genes were up-regulated in Gem+Rom+Cistreated J82 cells, giving rise to significant enrichment of this function (p = 0.008, Fisher’s exact
test). Although up-regulation of 32 ROS- and 57 cell death-associated genes was induced by
Gem+Rom+Cis in J82 cells, ROS-associated genes were not significantly enriched (p = 0.11,
Fisher’s exact test). Although Gem+Rom+Cis induced some of commonly regulated genes
associated with ROS, cell death, and drug resistance in both cells, much fewer genes were
significantly induced in J82-Ras cells than in J82 cells (Fig. 3.5a & 3.5c). In addition, more
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genes associated with DNA repair, autophagy, and drug transport were up-regulated by
Gem+Rom+Cis in J82 than in J82-Ras cells. None of the DNA repair- associated genes was
detectably down-regulated in J82 and J82-Ras cells, and none of the autophagy- or drug
transport-associated genes was detectably down-regulated in J82-Ras cells while a few of genes
were down-regulated in J82 cells (Fig. 3.5b). Taking these results together, the transcriptome
analysis revealed that drug resistance-associated genes were significantly induced in J82, but not
in J82-Ras cells, whereas the ROS-associated genes were significantly induced in J82-Ras, but
not in J82 cells. The higher level of cell death-associated genes significantly induced by
Gem+Rom+Cis in J82-Ras than in J82 cells was closely correlated with the preferential
induction of death in J82-Ras vs. J82 cells. The higher numbers of DNA repair-, autophagy-, and
drug transport-associated genes induced by Gem+Rom+Cis in J82 than in J82-Ras cells were
correlated with the preferential suppression of clonogenic survival in J82-Ras vs. J82 cells.
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Figure 3.5 Transcriptomic profiles associated with Gem+Rom+Cis. J82 and J82-Ras cells were treated with
Gem+Rom+Cis at their IC10 doses for J82-Ras cells for 48 h to induce differential cell death. (a) Heatmap of 179
differentially expressed genes (>2-fold change, FDR<0.05), induced by Gem+Rom+Cis, that are functionally
associated with ROS, cell death, or drug resistance. Color code represents the z-score of the expression. (b) Venn
diagram of differentially regulated genes, induced by Gem+Rom+Cis, functionally associated with ROS, cell death,
drug resistance, DNA repair, autophagy, or drug transport in J82 and J82-Ras cells were compared. (c)
Quantification of up-regulated ROS-, cell death- and drug resistance-associated gene expressions. Upper panel
shows the folds of increases. Lower panel shows the associated p-values. Fisher’s exact test was used to obtain
statistical significance: *p < 0.05, **p < 0.01, not significant (NS) p > 0.05.

113

Figure 3.5 (continued)
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Figure 3.5 (continued)
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Figure 3.5 (continued)
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3.3.5 BiP contributed to cell death induced by Gem+Rom+Cis
The BiP is known to support tumorigenesis and anti-apoptosis and is the key modulator
for UPR involved in cellular response to stress, autophagy, and apoptosis [39, 40]. BiP helps the
resistance to Gem [8], indicating an association between UPR with drug resistance. I detected
that BiP was elevated by Gem+Rom+Cis in both J82 and J82-Ras cells (Fig. 3.6a), as well as
T24 and SW780 cells (Fig. 3.7). Using gain- and loss-of-function approaches, BiP was
ectopically expressed by constant transfection and knocked down BiP by specific shRNAs in J82
cells, resulting in J82-BiP-1 and -2, as well as shBiP-1 and -2 cell lines, respectively (Fig. 3.6b).
Treatment with Gem+Rom+Cis induced increases of BiP in these cells (Fig. 3.6c). Interestingly,
ectopic expression, but not knockdown, of BiP resulted in increased susceptibility of J82 cells to
Gem+Rom+Cis for cell death; in contrast, knockdown of BiP appeared to increase moderate
resistance to Gem+Rom+Cis (Fig. 3.6d). These results indicated a novel role of elevated BiP
played in supporting cell death but not drug resistance in UC cells in response to
Gem+Rom+Cis.
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Figure 3.6 BiP contributed to cell death induced by Gem+Rom+Cis. (a) J82 and J82-Ras cells were treated with
Gem+Rom+Cis at their IC10 doses for 0, 6, 12, 24, and 48 h. (b) J82 cells were constantly transfected with a BiP
expression vector to result in J82-BiP-1 and -2 cell lines. J82 cells were constantly transfected with BiP-specific
shRNAs vectors to result in J82-shBiP-1 and -2 cell lines. (c & d) J82-BiP-1, BiP-2, shBiP-1, and shBiP-2, as well
as J82-Ras cells were treated Gem+Rom+Cis. (a to c) Cell lysates were prepared and analyzed by immunoblotting
using specific antibodies to detect levels of BiP with β-actin as a control, and these levels were quantified by
densitometry. Levels of BiP (BiP/actin) were calculated by normalizing with the level of β-actin and the level set in
control cells as 1 (X, arbitrary unit). (d) Cell viability was determined, and relative cell viability was normalized by
the value determined in untreated counterpart cells, set as 100%. Columns, mean of triplicates; bars, SD. The p value
was adjusted for multiple comparisons by using the Simes method. Statistical significance is indicated **p < 0.01,
***p < 0.001. All results are representative of three independent experiments.
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Figure 3.7 BiP induced by Gem+Rom+Cis in T24 and SW780cells. (a) T24 and (b) SW780 cells were treated with
Gem+Rom+Cis (G+R+C) for 48 h. Cell lysates were prepared and analyzed by immunoblotting using specific antibodies to
detect levels of BiP, with β-actin as a control, and these levels were quantified by densitometry. Levels of BiP (BiP/actin) were
calculated by normalizing with the level of β-actin and the level set in control cells as 1 (X, arbitrary unit). All results are
representative of three independent experiments.
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3.3.6 Efficacy of the Gem plus Rom+Cis regimen in controlling J82-Ras CDXs
In the standard protocol of the Gem plus Cis regimen to treat UC patients, 1000 mg/m2
Gem is given at days 1, 8, & 15, and 70 mg/m2 Cis is administered at day 2 (Table 3-4) [5, 6]. In
treating lymphoma or refractory solid tumors, 8 to 17.5 mg/m2 Rom is given at days 1, 8, & 15
(Table 3-2) [30, 41]. Calculations based on NCI’s Equivalent Surface Area Dosage Conversion
Factors [41] suggest that administering 1000 mg/m2 Gem, 15 mg/m2 Rom, and 70 mg/m2 Cis into
humans is equivalent to administering 324 mg/kg Gem, 5 mg/kg Rom, and 23 mg/kg Cis into
mice (Table 3-2). Considering the synergy and toxicity [5, 41] of Gem+Rom+Cis, I formulated
dose-reduced combination regimens containing 20 mg/kg Gem, 1 mg/kg Rom, and/or 5 mg/kg
Cis. As shown in Fig. 3.8a & 3.8b, using animal body weight loss to detect adverse side effects
[42], I determined drug-administering schedules for tolerable regimens and protocols. Although
mice administered with combination regimens appeared to gain weight less efficient than the
control group, animals did not lose body weight (Fig. 3.8b) or show any visible adverse side
effects, such as inability to move, eat, or drink, etc. Administering mice (i.p.) with the triple
combination Gem plus Rom+Cis regimen for 2 consecutive cycles, followed by 1-day of
intervals after the 2nd, 3rd, and 4th cycles of treatment (Table 3-4) was well tolerated and safe to
mice.
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Table 3-4 Standard protocols of clinical anti-cancer regimens converted for mouse use.
Regimen

Cancer type

Gem
plus Cis

UC

Drug dosage in
humans

Drug dosage
converted for
mouse study

Schedule

Gem, 1000 mg/m2

Gem, 324 mg/kg

Day 1, 8 & 15

Cis, 70 mg/m2

Cis, 23 mg/kg

Day 2

for humans

Lymphoma and
Rom, 8-17.5 mg/m2
Rom, 5 mg/kg
Day 1, 8 & 15
Refractory solid
tumor
UC: Urothelial carcinoma; Gem: gemcitabine; Rom: romidepsin; Cis: cisplatin
Rom

Determining the ability of the Gem plus Rom+Cis regimen to control tumor development
in vivo, I implanted J82-Ras cells subcutaneously into the flank area of nude mice. Mice
developing CDX tumors reaching ~18 mm3 were admitted into the treatment study. Tumor
volume was measured, and histo-pathological examination was performed during necropsy (day
17) 4 days after the last treatment (day 13) (Fig. 3.8a & 3.8c). I observed that two treatment
cycles of these regimens effectively controlled CDXs; however, tumors appeared to become
resistant to the Rom+Cis and the Gem plus Cis regimens afterward (Fig. 3.8c). In contrast, Gem
plus Rom+Cis was highly efficacious in controlling CDX development throughout treatment
cycles. Analysis of final tumor volume revealed a growth of CDXs in 17 days to ~480%, ~270%,
~300%, and ~110% of their original volume in mice treated with vehicle, Rom+Cis, Gem plus
Cis, and Gem plus Rom+Cis, respectively (Fig. 3.8d). Comparing tumor weights showed the
final tumor/control ratio (T/C) of tumors isolated from mice at day 17 that T/C ratio of CDXs at
0.44/1.0, 0.53/1.0, and 0.17/1.0 isolated from mice treated with Rom+Cis, Gem plus Cis, and
Gem plus Rom+Cis, respectively. The result verified the efficacy of these regimens in
controlling CDX development. The results also indicated that the Gem plus Rom+Cis regimen
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was more efficacious than double combination regimens in controlling CDX development and
resistance.
Histological examination of isolated tumors (Fig. 3.8e) revealed an average of~41, ~30,
~40, and ~1 mitotic figures per HPF in tumor tissues isolated from mice treated with vehicle,
Rom+Cis, Gem plus Cis, and Gem plus Rom+Cis, respectively (Fig. 3.8f & 3.8g). Necrosis area
was detectably higher in tumors isolated from mice treated with Gem plus Rom+Cis than in mice
treated with vehicle, Rom+Cis, or Gem plus Cis at an average of ~93% vs. ~3% vs. ~13% vs.
~5%, respectively. I also used the terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay to detect apoptotic cells in tumor tissues and cultured cells. The TUNEL assay
determined that Gem+Rom+Cis induced apoptosis of cultured cells in vitro but did not increase
the apoptotic cell population in tumors (Fig. 3.9). These results indicated that the Gem plus
Rom+Cis regimen inhibited proliferation and induced death via necrosis but not apoptosis, of
tumor cells more efficaciously than the Rom+Cis and the Gem plus Cis regimen in treating
animals.
To determine the ability of Gem plus Rom+Cis regimen to control resistant tumors from
animals treated with the standard Gem plus Cis regimen, I isolated growing J82-Ras CDXs from
animals after 5 cycles of treatment with the Gem plus Cis regimen (Fig. 3.8c) and developed into
GC-resistant J82-Ras cells. GC-resistant J82-Ras cells were highly resistant to Gem+Cis
treatment with an increased viability from ~72% (parental J82-Ras) to 90% but still susceptible
to Gem+Rom+Cis (Fig. 3.8h). My in vivo study showed that GC-resistant J82-Ras CDXs still
responded to the Gem plus Rom+Cis regimen, but not Gem plus Cis (Fig. 3.8i). Analysis of final
tumor volume revealed a growth of CDXs for 17 days to ~395%, ~360%, and ~211% of their
original volume in mice treated with PBS, Gem plus Cis, and Gem plus Rom+Cis, respectively
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(Fig. 3.8j). Comparing tumor weights showed the final tumor/control ratio (T/C) of tumors
isolated from mice at day 17 that T/C ratio of CDXs at 0.81/1.0 and 0.44/1.0 isolated from mice
treated with Gem plus Cis and Gem plus Rom+Cis, respectively. The results verified the ability
of Gem plus Rom+Cis to control GC-resistant CDXs.
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Figure 3.8 Efficacy of the Gem plus Rom+Cis regimen in controlling J82-Ras CDXs. (a) The immuno-deficient
nu/nu (nude) mice, 4 per group, were injected (i.p.) with PBS (V, control), 1 mg/kg Rom mixed with 5 mg/kg Cis
(Rom+Cis, R+C), 20 mg/kg Gem followed by 5 mg/kg Cis (Gem plus Cis, G plus C), and Gem plus Rom+Cis (G
plus R+C) for 5 treatment cycles at indicated days as scheduled with 0, 1, or 2 days of interval. (b) Body weight was
measured every 2 days to determine body weight loss for revealing adverse side effects of a regimen on animals. (c)
Two and half x 106 J82-Ras cells were mixed with Matrigel and inoculated into flank areas of nude mice. Tumor
volume was measured with a caliper and determined with a formula (length x width2 x ½) [43]. Mice developing
CDXs reaching ~18 mm3 were entered into the treatment study (day 1). Nude mice, 4 per group, were administered
(i.p.) with PBS (V, control), Rom+Cis (R+C), Gem plus Cis (G plus C), and Gem plus Rom+Cis (G plus R+C) at
indicated days for 5 treatment cycles. Tumor volume was measured daily. Mice were histo-pathologically examined
during necropsy at day 17. (d) Tumor volume at days 1 and 17 was presented in mean ± SD. Changes of tumor
volume (%) were calculated by T17 (tumor volume determined at day 17)/T1 (tumor volume determined at day 1).
Average weight of tumors isolated at day 17 was measured, mean ± SD. Final tumor/control ratio (T/C) was
calculated by T (mean tumor weight of treatment group)/C (mean tumor weight of control group) of tumors isolated
from mice at day 17. (e) Representative tumors were shown. (f) Histological features of representative tumors
isolated from control mice and mice treated with Gem plus Rom+Cis were shown. White arrows indicate mitotic
cells, and black arrows indicate necrosis area (irreversible damage). Images were taken at 400x; scale bar, 50 µm.
(g) Necrosis areas were analyzed using ImageJ software [62], and mitotic cells were determined. Necrosis areas (%)
and mitotic figures/cells, identified in tumors isolated from control mice and mice treated with combination
regimens, were averaged from 10 high power fields (HPFs) (400x). (h) GC-resistant J82-Ras cell line was
established from growing tumors from mice treated with the Gem plus Cis regimen. Parental J82-Ras and GCresistant J82-Ras cells were treated Gem+Rom+Cis for 48 h, and cell viability was determined. (i) As performed
above in (c), 2.5 x 106 GC-resistant J82-Ras cells were mixed with Matrigel and inoculated into to nude mice to
develop detectable CDXs, followed by treatments with the Gem plus Rom+Cis or the Gem plus Cis regimen. (j) The
efficacy in controlling GC-resistant J82-Ras CDXs was determined as performed above in (d). Statistical
significance, indicated by *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3.8 (continued)
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Figure 3.8 (continued)
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Figure 3.8 (continued)
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Figure 3.9 TUNEL assay. (a) J82-Ras cultures were treated with Gem+Rom+Cis for 24 h, rinsed, and fixed with
3.7% formaldehyde. (b) Paraffin embedded tissues were deparaffinized and rehydrated. Then, cultures and tissues
were examined with the TACS 2 TdT-DAB In Situ Apoptosis Detection Kit (Trevigen, MD, USA) to detect
apoptotic cells. Samples were counter-stained by methyl green. Images were taken at 400x; scale bar, 50 µm. Black
arrows indicate apoptotic cells.
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3.3.7 Efficacy of Gem plus Rom+Cis in controlling T24 CDX
Determining the ability of the Gem plus Rom+Cis regimen to control CDXs was not
limited to J82-Ras CDXs, I included the tumorigenic UC T24 cell line, which carries the
endogenous oncogenic H-Ras gene. Initially, I treated T24 cells with Gem, Rom, and/or Cis at
their IC10 doses and detected double and triple combinations of these agents synergistically
induced cell death; and Gem+Rom+Cis was more effective than double combinations in
inducing cell death (Fig. 3.10a-1 & 3.10a-2). Subsequently, I determined that Gem plus
Rom+Cis was also highly efficacious in controlling T24 CDX development (Fig. 3.10b).
Analysis of final tumor volume revealed a growth of CDXs in 17 days to ~433% and a reduction
to ~72% of their original volume in mice treated with PBS and Gem plus Rom+Cis, respectively
(Fig. 3.10c). Comparing tumor weights (final T/C at 0.17/1.00) verified the ability of Gem plus
Rom+Cis to effectively control T24 CDXs. Histological examination revealed an average of ~27
and 0 mitotic cells and ~23% vs. ~65% necrosis area per HPF in tumor tissues isolated from
mice treated with PBS and Gem plus Rom+Cis, respectively (Fig. 3.10d). These results indicated
that the Gem plus Rom+Cis regimen was also effective in inhibiting proliferation and inducing
death of T24 CDX tumor cells in vivo, and the ability of Gem plus Rom+Cis to control CDXs
was not limited to one UC cell type.
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Figure 3.10 Efficacy of Gem plus Rom+Cis in controlling T24 CDX. (a-1 & a-2) T24 cells were treated with
Gem (G), Rom (R), and/or Cis (C) for 48 h, cell viability was determined (a-1), and combined effects were
calculated (a-2) to reveal combination indices <1 for synergistic effects. (b) Five x 106 T24 cells were mixed with
Matrigel and inoculated into flank areas of nude mice. Tumor volume was measured with a caliper and determined
with a formula (length x width2 x ½) [42]. Mice developing CDX tumors reaching ~18 mm3 were entered into the
treatment study (day 1). Nude mice, 4 per group, were administered (i.p.) with PBS (V, control) and Gem plus
Rom+Cis (G plus R+C) at indicated days for 5 treatment cycles. Tumor volume was measured daily. Mice were
histo-pathologically examined during necropsy at day 17. (c) Tumor volume at days 1 and 17 was presented in mean
± SD. Changes of tumor volume (%) were calculated by T17 (tumor volume determined at day 17)/T1 (tumor
volume determined at day 1). Average weight of tumors isolated at day 17 was measured, mean ± SD. Final
tumor/control ratio (T/C) was calculated by T (mean tumor weight of treatment group)/C (mean tumor weight of
control group) of tumors isolated from mice at day 17. (d) Tumors isolated from mice treated with PBS or Gem plus
Rom+Cis were histologically examined to determine necrosis and mitotic figure. Necrosis (%) and mitotic cells
were determined and averaged from 10 HPFs, presented in mean ± SD. Statistical significance, indicated by *p <
0.05, ***p < 0.001.
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Figure 3.10 (continued)
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3.4 Discussion
In this communication, I demonstrated, for the first time, that the triple combination Gem
plus Rom+Cis regimen was highly efficacious and more efficacious than the standard double
combination Gem plus Cis regimen in suppressing cell viability, drug resistance, and CDX
development of the UC J82, J82-Ras, T24, and/or SW780 cells. Gem plus Rom+Cis was also
efficacious in controlling GC-resistant J82-Ras CDXs. My results strongly suggest that the Gem
plus Rom+Cis regimen should be seriously considered to control UC malignancy and recurrence.
My in vitro studies indicated that Gem+Rom+Cis was able to synergistically induce
apoptotic cell death and reduce drug resistance/clonogenic resistance of UC cells more
effectively than double combinations. Gem+Rom+Cis also showed a preferential suppression of
viability and drug resistance in the oncogenic H-Ras expressing J82-Ras vs. J82 cells. The
transcriptome analysis revealed that a higher level of cell death-associated genes was
significantly induced by Gem+Rom+Cis in J82-Ras than in J82 cells, and ROS-associated genes
were significantly induced in J82-Ras but not in J82 cells. In contrast, drug resistance-associated
genes were significantly induced in J82, but not in J82-Ras cells. In addition, higher numbers of
DNA repair-, autophagy-, and drug transport-associated genes were induced by Gem+Rom+Cis
in J82 than in J82-Ras cells. These discrepancies support the mechanism for Gem+Rom+Cis to
preferentially induce cell death and reduce drug resistance in J82-Ras cells vs. J82 cells. More
than 80% of UCs are associated with the aberrant induction of the growth factor receptor (GFR)
to the Ras-ERK pathway [44, 45]. My in vivo studies verified that the Gem plus Rom+Cis
regimen was highly efficacious in controlling CDXs of J82-Ras and T24, which carries the
oncogenic endogenous H-Ras gene. Thus, the Gem plus Rom+Cis regimen may particularly
target advanced UCs with aberrant GFR-Ras-ERK pathways.
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Induction, instead of suppression, of the ERK-Nox pathway and ROS played important
roles in Gem+Rom+Cis-induced apoptosis. The Ras-ERK pathway is often associated with cell
proliferation and survival of cancers [46]. Mek inhibitors, such as binimetinib and trametinib,
have been shown to suppress tumors, such as melanomas, where the ERK pathway is overactive
[46-48]. However, using Mek inhibitors alone often comes with drug resistance due to the
feedback reactivation of the ERK pathway [46, 48]. Thus, Mek inhibitors are used in
combination with other drugs, such as binimetinib combined with the B-Raf inhibitor
encorafenib, to treat cancers and prevent drug resistance [47, 48]. In contrast, piled studies
indicate that enhancing the ERK pathway by anticancer regimens, containing romidepsin, instead
of suppressing the ERK pathway, results in activating the ERK pathway to induce Nox1 and
elevate ROS, leading to enhanced cell death in various cancer cells, including urinary bladder,
breast and colorectal cancer cells [18-21, 49]. In these studies, using the Mek inhibitor U0126 to
block the ERK pathway to the downstream Nox-ROS pathway attenuated romidepsin-induced
cell death, clearly indicating that the romidepsin-induced ERK pathway is essential for cell
death, but not survival. My studies revealed that ROS elevation was required for inducing the
ERK-Nox pathway, and the ERK-Nox pathway was also required for ROS elevation. Gem and
Cis have been shown to induce mitochondrial ROS for inducing cell death [31, 50]. Nox family
members play major roles in ROS production [29, 33]. Accordingly, Gem+Rom+Cis may induce
both mitochondria- and Nox-dependent ROS to jointly elevate ROS to a lethal level, causing
caspase activation, PARP proteolysis, DNA oxidation, and DNA damages. In addition, Gem
inhibits DNA replication [51], and Cis damages DNA [35]. It is conceivable that Gem+Rom+Cis
induced DNA damage and inhibited DNA repair directly, induced ROS-dependent DNA
oxidation and damage, and inhibited PARP-dependent DNA repair, thereby holistically
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contributing to synergistic induction of cell death and suppression of clonogenic survival/drug
resistance. I detected that Rom+Cis induced higher levels of cell death than Cis+Gem, but
Cis+Gem was more effective than Rom+Cis in suppressing clonogenic survival. Apparently,
mechanisms for inducing cell death were not fully overlapped with suppressing clonogenic
survival. I also detected that Cis was less effective than Rom and Gem in reducing GSH;
however, Cis facilitated Rom and Gem to reduce GSH and clonogenic survival. GSH is the most
abundant intracellular antioxidant and forms conjugates with Cis for exportation, resulting in
resistance to Cis [3, 35, 52, 53]. Thus, a combination of Gem+Rom+Cis was complementary to
become more effective than any double combinations in inducing cell death and reducing
clonogenic survival/drug resistance.
My investigation revealed the key UPR modulator BiP induced by Gem+Rom+Cis to
support cell death. However, other studies have shown the role BiP plays in supporting
tumorigenesis, anti-apoptosis, and drug resistance to Gem [8, 39, 40]. The gain- and loss-offunction studies indicated that ectopic expression, but not knockdown, of BiP resulted in
increased susceptibility of cells to Gem+Rom+Cis for death, indicating a novel role of
elevated BiP played in supporting apoptosis, but not anti-apoptosis, in response to
Gem+Rom+Cis. Although BiP has been reportedly associated with poor prognosis and chemoresistance in pancreatic, brain, liver, lung, and breast cancers [54], BiP has also been shown to
play a role in inducing apoptosis [55-57]. BiP has been shown to interact with the secreted
protein acidic and rich in cysteine (SPARC) to induce apoptosis through the PERK/eIF2α and
IRE1α/XBP1 pathways in colorectal cancer cells [54]. BiP interacts with the prostate apoptosis
response-4 (Par-4) at the cell surface to activate FADD/caspase-8/caspase-3 pathway and induce
extrinsic apoptosis [55]. Par-4 is a tumor suppressor that is usually downregulated in oncogenic
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Ras-expressing cells [58, 59], and overexpression of Par-4 enhances apoptosis in oncogenic Rasexpressing fibroblasts [57]. Romidepsin treatment may result in elevating Par-4 level, and
overexpression of Par-4 sensitizes recurrent tumors to chemotherapy [59]. Cisplatin treatment
may enhance the apoptosis of Par-4-expressing Wilms’ tumor cells through the ER apoptotic
pathway with Par-4 interaction with BiP [57]. However, the extent to which Par-4 and/or the
SPARC to PERK/eIF2α and IRE1α/XBP1 pathways are involved in BiP-mediated cell death
induced by Gem+Rom+Cis remains to be clarified.

3.5 Conclusion
The current standard regimen for advanced UCs is Gem plus Cis [5, 60, 61]. My studies
demonstrated that integration of Rom into the double combination regimen, resulting in the Gem
plus Rom+Cis regimen, may significantly improve its efficacy in controlling UCs. I formulated
the dose-reduced combination Gem plus Rom+Cis regimen with less than 6% Gem, 25% Rom,
and 25% Cis of their clinically equivalent doses that was well tolerated in animals. Because
Gem, Rom, and Cis are FDA-approved to treat cancers, the safe dose-reduced Gem plus
Rom+Cis regimen shall be rapidly translated into clinical studies to improve chemotherapy for
controlling the development and recurrence of advanced UCs, especially Ras-ERK-activated
UCs, ultimately improving patients’ quality of life.
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Chapter 4
Additional data on the effect of Gem plus Rom+Cis on metastasis markers
and establishing metastasis model of MDA-MB231
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Abstract
Metastasis is a major cause of cancer related death. Targeting metastasis is one of the
cancer treatment strategies that need to be investigated. Previous research results showed that the
triple combination of gemcitabine, romidepsin, and cisplatin could control triple negative breast
cancer (TNBC) development in vitro and in vivo. In this chapter, the possibility of using the
triple combination to treat an in vitro model of triple negative breast cancer was investigated.
An in vitro invasion assay was used to investigate the invasiveness of TNBC cell lines,
MDA-MB231, and MDA-MB468. Anchorage dependent growth (AIG) was used to investigate
whether the combination could suppress epithelial to mesenchymal transition, which is related to
invasiveness and metastasis. The results showed that the triple combination treatment suppressed
in vitro invasion of the TNBC cell lines and suppressed AIG. Immunoblotting results showed
that the triple combination reduced vascular endothelial growth factor (VEGF), matrix
metalloprotease-9, and vimentin while promoting the cell-cell adhesion molecule, E-cadherin, of
MDA-MB231. These results suggest that the combination of gemcitabine plus cisplatin and
romidepsin plays a role in suppressing metastasis. The possibility of using immunocompromised
mice (nu/nu) as an in vivo metastasis model was also assessed. 5 x 105 MDA-MB231 cells were
injected via the tail vein into nude mice. Autopsy results showed that cells established colonies in
the lungs, ovaries, lymph nodes, and the abdominal walls, which indicated that this cell line has
high metastatic ability and it is capable to be used for establishing a metastatic mouse model.
In conclusion, the triple combination is effective in suppressing cellular invasion and I
established an in vivo model for metastasis to be used for the future studies.
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4.1 Introduction
Metastasis is a complex biological process that is a major cause of cancer related death,
as 90% of cancer related death was caused by metastasis [1, 2]. Despite advances in breast
cancer diagnostics and treatments, there is still no cure for metastatic breast cancer. Metastatic
breast cancer can reduce the 5-year relative survival rate of patients from 98.8% to 27.4 % [1].
Triple negative breast cancer (TNBC) has the lowest 5-year survival rate of all subtypes, at
11.5% [2]. TNBC has a higher 5 year recurrence rate than non-TNBC at 38.4 vs 29.5%. 85% of
TNBC recurrence occur at distant sites [3].
Targeted therapy, such as hormone therapy, has become a preferred way to treat hormone
receptor (HR) positive breast cancer [4]. Biological factors involved in invasion and metastasis
can be categorized into angiogenesis factors, proteolytic enzymes, adhesion proteins, and
cytoskeleton remodeling factors [5, 6]. Angiogenesis factors, such as vascular endothelial growth
factor (VEGF), induce angiogenesis, and facilitate cancer cell growth. Proteolytic enzymes, such
as matrix metalloproteases (MMPs), digest the extracellular matrix surrounding the cells to
facilitate cell mobility. The upregulation of MMP9 is known to be associated with lymph node
metastasis in breast cancer [7]. Changes in the cytoskeleton remodeling factors vimentin, and
adhesion proteins E-cadherin, facilitate the epithelial to mesenchymal transition (EMT) [8, 9].
EMT is a transitional process that is correlated with tumor aggressiveness and poorer prognoses
[8, 9].
Metastatic breast cancer treatments depend on molecular subtypes. Targeted therapy,
such as hormone therapy, has become a preferred way to treat hormone receptor (HR) positive
breast cancer. However, HR negative subtypes, such as TNBC, do not have specific receptors to
target; therefore, chemotherapy is still the best strategy to combat this breast cancer subtype.
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Many studies demonstrate that combination therapy is more effective than single drug
chemotherapy, as combination therapy tends to target multiple pathways at the same time.
Previously, an effective combination of gemcitabine, romidepsin and cisplatin (Gem plus
Rom+Cis) has been proposed. Platinum drugs, such as cisplatin, are still commonly used to treat
TNBC [10]. This type of drug causes apoptosis by inducing DNA damage and preventing single
strand break repair; thus, cisplatin targets rapidly dividing cells and is effective against TNBC
[10-12]. Gemcitabine, an inhibitor of DNA synthesis, is used in combination with cisplatin to
treat many types of cancer and has been reported to improve outcomes and prognoses of
metastatic TNBC patients [13]. Romidepsin, a histone deacetylase class I inhibitor, is effective at
inducing apoptosis in many types of cancer cells including those of the bladder, colorectal, and
breast tissues [14-20]. Results from previous chapters show that using these three drugs in
combination is more effective in inducing tumor cell death in vitro and controlling tumor
development in the cell-derived xenograft (CDX) model than combinations of Gem +Cis or
Rom+Cis.
Yet, the efficacy of Gem plus Rom+Cis combination on metastasis of TNBC has not
been determined. Hence, this study further investigated the effects of Gem plus Rom+Cis on
suppressing invasion and anchorage independent growth of TNBC cell lines, and establishing
metastatic MDA-MB231 mice model.

4.2 Materials and Methods
4.2.1 Cell cultures and Reagents
MDA-MB231 and MDA-MB468 cells (American Type Culture Collection, Rockville,
MD, USA) were maintained in DMEM and supplemented with 10% fetal bovine serum [16].
Cultures were supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin in 5% CO2 at
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37 °C and routinely subcultured every 2 to 3 days. Stock aqueous solutions of gemcitabine,
romidepsin, cisplatin (MedKoo, Morrisville, NC, USA), and chloromethyl–
dichlorodihydrofluorescein–diacetate (CM–H2DCF–DA) (Invitrogen, Carlsbad, CA, USA) were
prepared in Dimethyl sulfoxide (DMSO) and diluted in a culture medium for assays. Stock
aqueous solutions of N-acetyl-l-cysteine (NAC) (Alexis, San Diego, CA, USA) were prepared in
distilled water and diluted in a culture media for assays [14]. The experiment was done in
triplicates.

4.2.2 Cell viability assay
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (Travigen, Gaithersburg, MD, USA)
was used to measure cell viability [14, 15]. 5 × 103 cells were seeded into each well of 96-well
culture plates. After treatments, cells were incubated with MTT reagent for 4 hours, followed by
an incubation period with a detergent reagent for 24 h. The reduced MTT reagent in cultures was
quantified with an ELISA reader (Bio-Tek, Winooski, VT, USA). The experiment was done in
triplicates.

4.2.3 Immunoblotting
Cells were treated for 48 hours, tumors isolated from the xenograft model were processed
immediately, then cell lysates were prepared and protein concentrations were measured using the
BCA assay (Thermo, Rockford, IL, USA). [14-18] Equal amounts of cellular proteins were
resolved by electrophoresis in 10% SDS–polyacrylamide gels and transferred to nitrocellulose
filters for immunoblotting while using specific antibodies to detect MMP9, E-cadherin, vimentin
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(Cell Signaling), VEGF, and β-actin (Santa Cruz, Santa Cruz, CA, USA). Antigen-antibody
complexes on filters were detected by the SuperSignal West Dura kit (Thermo Fisher, Rockford,
IL, USA). The experiment was done in triplicates.

4.2.4 Trans-well invasion assay
The in vitro cell invasion assay was performed using 24-well Transwell insert chambers
with an 8.0 µm pore size polycarbonate filter (Costar, Corning, NY, USA). The amount of 2×104
cells in serum-free DMEM was seeded on top of a Matrigel-coated filter (BD Biosciences,
Franklin Lakes, NJ, USA) in each insert chamber. Insert chambers were then placed into wells
on top of culture medium containing 10% horse serum as a chemoattractant. The in vitro
migration assay was performed using 24-well Transwell insert chambers with a polycarbonate
filter not coated in Matrigel. After 24 h, cells were fixed with cold 70% ethanol and stained with
crystal violet. The invasive ability of cells was determined by the number of cells translocated to
the lower side of filters [20]. The relative invasion was normalized by cell viability, then the
relative values were normalized by the value determined in untreated counterpart cells, set as
100%. The experiment was done in triplicates.

4.2.5 Anchorage-independent growth assay
Cells were treated with anticancer agents for 48 h. Then, the amount of 1×104 cells was
mixed with soft agar consisting of 0.4% low-melting agarose (Fisher, Fair Lawn, NJ, USA) in a
mixture (1:1) of DMEM, plated on top of a 2% low-melting agarose base layer in 60-mm culture
dishes, and maintained for 14 days to develop cell colonies [20].

150

4.2.6 Metastasis mouse model
Mice were housed in sterile cages in a temperature-controlled room with 12 h light-dark
cycle at the University of Tennessee Laboratory Animal Facility. Mice were provided with
irradiated diet and water ad libitum. Athymic (nu/nu) nude mice were injected with 5 x 105
MDA-MB231 cells via the tail vein. Mice were euthanized by CO2 exposure followed by
cervical dislocation at day 30, and day 60 after tumor injection. Samples were then collected for
histological analysis. All animal procedures were approved by the University of Tennessee
Animal Care and Use Committee and were following the NIH Guide for the Care and Use of
Laboratory
4.2.7 Histological examination
Isolated tissues were fixed in neutral-buffered formalin and embedded in paraffin,
followed by hematoxylin and eosin staining of tissue sections for histopathological examination.

4.2.8 Statistical analysis
A Student t test was used to analyze statistical significance. Multiple comparison analysis
was evaluated using one-way ANOVA followed by post-hoc Tukey’s multiple comparison test
using SPSS software (IBM, Armonk, NY, USA). Statistical significance was indicated by *p <
0.05, **p < 0.01, ***p < 0.001; a p value < 0.05 was considered significant.
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4.3 Results
4.3.1 Gem+Rom+Cis reduces cellular invasion and anchorage independent growth of
TNBC cell lines.
This study focuses on how Gem+Rom+Cis affects the metastatic ability of TNBC cell
lines. IC10 of gemcitabine, romidepsin and cisplatin were determined in the non-tumorigenic
epithelial cell line MCF10A and triple negative breast cancer cell lines MDA-MB231 and MDAMB468 cell line using cell vitality assay. Three drugs were combined at their IC10 doses for
treatment of each cell line (Fig. 4.1a). Then the combination of Gem+Rom+Cis at IC10 was used
to treat MDA-MB231 and MDA-MB468 cells for trans-well invasion assay to determine
invasiveness. The results showed that Gem+Rom+Cis suppressed invasion of both MDA-MB231
and MDA-MB468 cell lines (Fig. 4.1b).
Anchorage independent cell growth (AIG) of MDA-MB231 and MDA-MB468 was
determined using the soft agar colony formation assay. Results revealed that the AIG was also
suppressed in both cell lines (Fig 4.1c). These results suggest that the triple combination could
reduce invasiveness and anchorage independence growth.
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Figure 4.1 Gem+Rom+Cis reduce cellular invasion and anchorage independent growth of TNBC cell lines.
MCF-10A, MDA-MB231 and MDA-MB468 cells were treated with Rom, Cis, Gem or combination of
Gem+Rom+Cis (G+R+C) at their IC10 doses for 24 h (b) or 48 h (a & c). (a) MTT assay kit was used to determine
cell viability. Relative cell viability was normalized by the value determined in untreated counterpart cells set as
100%. (b) Invasive activities after treatment of Gem+Rom+Cis were determined by counting the numbers of cells
translocated through a polycarbonate filter coated with matrigel in 10 arbitrary visual fields. The relative invasion
was normalized by cell viability, then the relative values were normalized by the value determined in untreated
counterpart cells, set as 100%. (c) Soft agar colony formation assay was used to determine cellular acquisition of
anchorage independent growth (AIG). 10,000 MDA-MB231 and MDA-MB468 cells were seeded in soft agar for 14
days. Cell colonies with a diameter of ≥0.1 mm were counted. Columns, mean of triplicates; bars, SD. Statistical
significance were determined by Tukey’s multiple comparison test (a) and student’s t-test (b-c), significance
indicated by *p < 0.05, **p < 0.01, ***p < 0.001. All results are representative of three independent experiments.

153

4.3.2 Gem+Rom+Cis altered protein level of metastasis related markers of TNBC cell line.
Cellular levels of proteins that are related to the metastasis process were quantified by
immunoblotting. MMP9 is a protease enzyme, VEGF is an angiogenesis factor, and E-cadherin
and vimentin are EMT markers. The results of immunoblotting revealed that the triple
combination treatment did not affect the levels of MMP9, vimentin, E-cadherin, and VEGF in
MCF10A cells (Fig. 4.2a). Levels of MMP9, vimentin, and VEGF in MDA-MB231 and MDAMB468 cell lines were decreased after treatment, while E-cadherin levels in MDA-MB231 cells
increased (Fig. 4.2b.) Immunoblotting of the MDA-MB468 cell line revealed that while the
triple combination reduces VEGF, MMP9, and vimentin, but the combination did not reduce the
level of E-cadherin (Fig. 4.2c). These results indicate that Gem+Rom+Cis treatment reduces
metastasis through the reduction of MMP9, VEGF, and EMT.

Figure 4.2 Gem+Rom+Cis change protein levels of metastasis related markers of TNBC cell line.
Immunoblotting of metastatic and EMT markers of (a) MCF10A, (b) MDA-MB231 and (c) MDA-MB468 cells.
Cells were treated with Gem+Rom+Cis (G+R+C) at their IC10 doses for 48h, then cell lysates were prepared and
analyzed by immunoblotting using specific antibodies to detect levels of VEGF, MMP9, E-Cadherin, and vimentin,
with β-actin as a control. Levels of VEGF, MMP9, E-cadherin, and vimentin were determined by densitometry and
were normalized with the level of β-actin, then the level set in control cells as 1.
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4.3.3 Establishing metastasis model of human TNBC in nude mice
To explore whether Gem+Rom+Cis could suppress metastasis in vivo or not, athymic
(nu/nu) nude mice were used to establish a mice model of metastatic TNBC. The metastasis
model was established by injecting 5 x 105 MDA-MB231 cells into mice via the tail vein. Mice
were sacrificed at day 30 and day 60 after injection (Fig. 4.3a). Metastatic tumor was not
observed at day 30 (not shown). Biopsy results revealed that mice developed metastatic tumors
in the lungs, abdominal wall, lymph nodes, and ovaries 60 days post-injection (Fig. 4.3b and
4.3c).

Figure 4.3 Establishing metastasis model. (a) The immuno-deficient nu/nu (nude) mice were injected (i.v.) with 5
x 105 MDA-MB231 cells, then mice were sacrificed and examined at day 30 and 60. Samples were collected and
processed for histological analysis. (b) Picture of organs/body parts that contain tumors of mice at day 60 of
injection. Organs and body parts were inspected visually. (c) Histological features of representative metastasis
tumors from lungs, lymph nodes, ovaries, and abdominal walls of mice at day 60 after injection. Images were taken
at 100x; scale bar, 50 µm.
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4.4 Discussion
Results from experiments in this chapter demonstrated that the Gem+Rom+Cis regimen
is capable of controlling the invasiveness and EMT of triple negative breast cancer cells in vitro.
The results reveal that while treatment with triple combination does not change the level of
metastasis related proteins in non-cancerous cell line MDF-10A, Gem+Rom+Cis is able to
suppress invasion and anchorage independent growth in MDA-MB231 and MDA-MB468 cell
lines. This suppression of metastasis is possibly elicited by changing the levels of metastasis and
EMT related factors: MMP9 - a protease enzyme, VEGF - an angiogenesis factor, and Ecadherin and vimentin, which are EMT markers [7, 21-24].
Epithelial cells have to attach to a basement membrane and adjacent cells to grow and
proliferate. This process is known as anchorage. Without anchorage, epithelial cells can not
proliferate and undergo apoptosis [25-26]. Thus, anchorage independent cell growth (AIG) is
another hallmark of cancer that is associated with EMT and metastatic potential [26]. This
study shows that Gem+Rom+Cis altered protein levels of EMT related factors. From the
results, E-cadherin levels increased in the MDA-MB231 cell line. This upregulation of Ecadherin could contribute to the reduction of invasiveness since levels of E-cadherin were
found to be inversely associated with metastasis [21]. E-cadherin also induced anoikis, a form
of apoptosis induced by cell detachment, in a 3D cell culture environment [21-23]. Thus, AIG
was suppressed.
The level of E-cadherin in MDA-MB468 cells did not change when compared to
untreated control. This may be due to the fact that the level of E-cadherin in untreated MDAMB468 is higher than MDA-MB231 [22]. Having higher endogenous E-cadherin could affect
the mobility and invasiveness of the cells, as the results showed that the MDA-MB468 had lower
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percentage of relative invasion than MDA-MB231 cells. The mechanisms behind what makes
two cell lines have different responses to the combination are left open to further investigation.
Vimentin is another important marker of EMT. In this study, vimentin levels decreased in
both TNBC lines when detected by immunoblotting. Vimentin is associated with metastasis as
studies showed that silencing vimentin suppresses cellular invasiveness in MDA-MB231 cells
[23]. Vimentin is usually used as a marker for EMT, as it is highly expressed in dedifferentiated
cancer cells [24]. Vimentin also was found to be associated with chemoresistant cells [24].
Typically, the vimentin is used as an indicator of EMT in conjunction with other EMT-related
markers [7]. In this study, I used E-cadherin, in which the protein level is also increased in
MDA-MB231 after the cells are treated with the triple combination. These results suggest that
Gem plus Rom+Cis has the ability to suppress EMT by altering E-cadherin and vimentin protein
levels.
The triple combination demonstrates the ability to downregulate VEGF, an angiogenic
factor that is associated with invasion and metastasis [27, 28]. Suppression of VEGF was found
to suppress metastasis in many types of cancers, including liver, prostate, and breast cancer [2728]. Anti-angiogenic drugs, such as Bevacizumab, a VEGF monoclonal antibody was approved
by FDA and has been used to treat many types of cancer including using it in combination with
other chemotherapeutic agents to improve progression free survival rate of TNBC [29-31]. Thus,
the triple combination could suppress metastasis through interruption of angiogenesis.
MMP9, a protease that is associated with metastasis as it usually presents in higher grade
breast cancers [32, 33], is downregulated after triple combination treatment. These results
suggested that triple combination suppressed invasion of TNBC through downregulation of
MMP9; hence, TNBC cells with triple combination treatment could not effectively digest and
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move through the matrigel layer of the trans-well invasion assay. In addition, high serum levels
of MMP9 are linked to the development of metastases in the lung and lymph nodes [32, 33].
Metastasis is suppressed in the MMP9 deficient mice [34]. MMP9 was also found to facilitate
receptor binding of VEGF by releasing it from the ECM [34]; thus, decreasing both MMP9 and
VEGF levels can potentially prevent tumor angiogenesis.
My study showed that the combination of Gem+Rom+Cis has the potential to suppress
metastasis in vitro. However, the in vivo study needs to be done in the future to clarify the
potency of Gem plus Rom+Cis on metastatic breast cancer. Data from this study showed that
MDA-MB231 could be used to establish the metastatic model in mice. The results showed that
MDA-MB231 metastasized not only to the lungs but also to the ovaries, lymph nodes, and the
abdominal wall of mice after tail vein injection. This indicates that MDA-MB231 is appropriate
to be used as a model for metastasis.

4.5 Conclusion
Metastasis of breast cancer is a threat to patients’ health and wellbeing that needs to be
taken seriously. My results suggest that Gem+Rom+Cis has a positive sign for metastasis
suppression and in vivo study should be conducted to clarify the potency of Gem plus Rom+Cis
on metastatic breast cancer.
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Chapter 5
Summary of significant findings, and Future direction
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5.1 Summary of significant findings
5.1.1 Formulated combination therapy reduced dosage use of each drug without
compromising efficacy
In this dissertation, I demonstrated that Gem plus Rom+Cis regimen is a safe and
efficacious treatment for cancer CDX models. Minimizing overlapping toxicities of the drugs is
one of the most important factors to consider when formulating a combination regimen to control
cancers. My investigation of the drug-related dose limiting effects shows that weight loss is
closely associated with the toxicity of Gem plus Rom+Cis regimen in mice. I also found that
tolerance level might be different between strands of mice, as Gem plus Rom+Cis is evidently
more toxic to nude mice than in BALB/c mice. This difference might be due to the mutation
involved in making Nu/nu mice immune deficient. However, when interval days were introduced
to the treatment plan, the toxicity of the regimen in nude mice became less toxic and resulted in a
non-toxic, tolerable, and safe regimen.
The Gem plus Rom+Cis regimen contained reduced doses of gemcitabine, romidepsin,
and cisplatin less than 6%, 25%, and 25%, respectively, of their current clinically equivalent
doses. Adding interval days between cycles of treatment reduced the toxicity of the combination
to a non-toxic level. The regimen is highly effective in controlling cancer development of breast
and bladder CDX models without detectable toxicity at the end of studies.
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5.1.2 Gem+Rom+Cis synergistically induces cell death and is more effective than double
combinations.
This dissertation demonstrated that the Gem+Rom+Cis regimen synergistically induced
cancer cell death and was more effective than double combination or single agent therapy. The
combination of Gem+ Rom+Cis at their IC10 doses synergistically induces cell death of breast
and bladder cancer (CI<1). The triple combination was shown to be the most effective treatment
for reducing cell vitality of transitional urinary bladder cancer cell line J82, J82-Ras, SW780,
and T24, as well TNBC cell line MDA-MB231 and MDA-MB468 when compared to the
combination of Cis+Gem, Rom+Cis or Rom+Gem, or the treatment of individual drugs. The
triple combination was also more effective in reducing colony formation and AIG, which are key
features of cancer that are associated with recurrence and aggressiveness. Furthermore, Gem plus
Rom+Cis was also more effective in controlling tumor development in CDX models than double
combinations.
Cisplatin generated DNA damage by crosslinking DNA, then, gemcitabine enhanced
DNA damage from cisplatin through the inhibition of DNA crosslink repair as well as caused
DNA damage through inhibition of DNA synthesis. The ability of romidepsin to induce ROS
production further caused oxidative damage to DNA. In addition, romidepsin also has the ability
to deplete cellular GSH, a thiol molecule that can render cisplatin inactive, which further
enhanced the ability of cisplatin to cause DNA damage (Fig. 5.1).
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Figure 5.1 Graphical summary of triple combination induced apoptosis. Cisplatin generates DNA damage by
promoting DNA crosslink. Gemcitabine promotes the inhibition of DNA crosslink repair and inhibition of DNA
synthesis. Romidepsin depletes cellular GSH and induces ROS production. Three drugs work together to generate
DNA damage, which leads to apoptosis.

5.1.3 ROS generation by Ras-ERK-Nox pathway plays roles in selective apoptosis induction
of Gem plus Rom+Cis regimen.
H-Ras is expressed in 30% of all tumors and has been associated with the aggressiveness
of cancer [3]. Thus, H-Ras is a good candidate for targeted therapy. The triple combination
showed preferential cell killing for oncogenic H-Ras expression cell line (J82-Ras), H-Ras
mutation cell line (T24), and was also effective in killing triple negative breast cancer cell lines
(MDA-231 and 468). Interestingly MDA-MB231 was reported to be Ras mutant positive cell
lines (K-Ras, and H-Ras mutation) [1, 2]. These results showed the versatility of this triple
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combination for many types of cancers and preferentially induced cell death in H-Ras expressing
cell lines.
My in vitro studies on bladder cancer cell lines reveal that the apoptosis of cancer cells
was induced through the Ras-ERK-Nox pathway. Induction of the Ras-ERK-Nox pathway
leading to ROS upregulation might be the key as to how Gem plus Rom+Cis induces apoptosis.
Since Nox-1 is downstream of the ERK pathway, elevated ERK activity triggers ROS generation
by Nox-1.
ROS is likely to play a significant role in the selectivity of the combination against H-Ras
expressing cells since the transcriptomic data shows that the ROS and cell death associated genes
were both significantly induced in J82-Ras, but not induced in J82.
ROS levels were elevated in bladder cancer and breast cancer cell lines post-treatment.
The addition of NAC to the combination treatment reduced ROS levels and consequently reverse
the cell killing effect. It is possible that ROS produced by the mitochondria and Nox-1
cooperatively elevate ROS levels to a lethal level. ROS elevation and PARP cleavage were
observed in vitro in both breast cancer and bladder cancer cell lines. The author proposed that
Gem+Rom+Cis treatment leads to ROS accumulation, which activates caspase to induce PARP
proteolysis. This leads to DNA damage and eventual apoptosis.

5.1.4 UPR modulator BiP was upregulated when treated cells with Gem+ Rom+Cis
regimen
My study shows the upregulation of BiP in bladder cell lines after Gem+Rom+Cis
treatment. The knockdown of BiP resulted in reduced cell killing by triple combination. This
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suggests that BiP plays a role in inducing cell death rather than promoting cell survival. The
conventional role of BiP is being the key modulator of the UPR pathway that supports
tumorigenesis by promoting cell survival and helping the cell avoid apoptosis induced by cellular
stress. However, BiP was shown to play a role in inducing apoptosis by interacting with SPARC
through the PERK/eIF2α and IRE1α/XBP1 pathways [4-8]. BiP also has been reported to
interact with Par-4 at the cell surface to activate the FADD/caspase-8/caspase-3 pathway to
induce extrinsic apoptosis [4-8].
The extent to which Par-4 and/or the SPARC to PERK/eIF2α and IRE1α/XBP1 pathways
are involved in BiP-mediated cell death induced by Gem+Rom+Cis still needs to be clarified.

5.1.5 Gem plus Rom+Cis reduce drug resistance and tumor reoccurrence in xenograft
models
Reoccurrence is a major problem in breast cancer. Combination therapy has been used as
adjuvant therapy for operable breast cancer and urinary bladder cancer [9-17]. For breast cancer,
a combination of cyclophosphamide, methotrexate, and fluorouracil [5-FU] is traditionally used
[9-11]. However, resistance and recurrence usually occur. My in vitro and in vivo studies
confirmed that tumors from GC-resistant cell lines were better controlled by Gem plus Rom+Cis
combination than the Gem plus Cis combination. My in vivo experiments showed that my new
combination could suppress tumor development in GC-resistant CDX models. In addition to that,
my in vitro studies indicate that Gem plus Rom+Cis could reduce drug resistance by decreasing
GSH levels and reducing clonogenic survival. GSH is an antioxidant molecule that is produced
in cells. The thiol group of GSH binds and inactivates anti-cancer drugs, especially platinum
drugs such as cisplatin [16]. GSH also facilitates platinum drug efflux by serving as a cofactor
170

for multidrug resistance protein 2 (MRP2) [16]. Thus, reducing GSH leads to increase sensitivity
to chemotherapeutic drugs.
Immunoblotting revealed that the triple combination therapy reduces vimentin and
increases E-cadherin levels in the MDA-MB231 cell line. This indicated that the cells possess
characteristics of epithelial cells rather than mesenchymal cells. Many studies have shown that
epithelial-like tumor cells were more sensitive to anti-cancer drugs than mesenchymal-like cells
[18, 23]. Thus, the Gem plus Rom+Cis regimen could potentially reduce drug resistance in
various types of cancers through the reduction of GSH and EMT.

5.1.6 Gem+Rom+Cis lower invasiveness and EMT in vitro
Gem plus Rom+Cis was shown to suppress invasiveness and AIG of triple negative
breast cancer cell lines through changing the protein level of MMP9, VEGF, vimentin, and Ecadherin. These proteins are associated with cancer cell invasion and metastasis; thus, it is
interesting to see the effectiveness of this triple combination in controlling MDA-MB231
metastasis of mice model.
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5.2 Conclusion
Estimation of new cancer cases in the US has increased from 1,762,450 cases in 2019 to
1,806,590 cases in 2020 [24, 25]. These numbers suggest that cancer is still a very serious health
problem in the US. Thus, highly effective cancer therapeutic regimens are urgently needed. The
development of a new single therapeutic drug is expensive and time-consuming. Developing one
drug might cost more than $2 billion [26], and could take approximately 15 years to get FDA
approval [27]. Formulating new regimens from FDA approved drugs is a cost-effective way to
generate novel efficacious regimens while bypassing the cost of new drug development. My
combination of Gem plus Rom+Cis contains already-approved FDA drugs, which make it more
affordable to develop the treatment.
I proved that this combination regimen is highly efficacious and safe in my animal
model. The triple combination controls tumor development through the induction of apoptosis,
reduction of drug resistance, and suppression of metastasis (Fig. 5.2). Gem plus Rom+Cis
synergistically induces cancer cell death through the induction of ROS via the MAPK pathway,
which leads to DNA damage and apoptosis. The triple combination also promotes apoptosis by
altering the modulation of the UPR pathway. Drug resistance was reduced by the triple
combination through the depletion of cellular GSH and suppression of EMT. Gem plus Rom+Cis
also suppressing the invasion and AIG, which are hallmarks of metastasis, by changing the levels
of proteins that involved.
My results have shown that the triple combination can effectively control tumor
development. Also, the ability to reduce drug resistance makes this regimen a promising
treatment for recurrent tumors. Translation of this regimen into clinical trials could ultimately be
an efficient way to reduce cancer related mortality and improve patients’ quality of life.
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Figure 5.2 Graphical summary of the triple combination therapy mechanisms. Gem plus Rom+Cis induces
apoptotic cell death through the induction of the Ras/ERK/Nox pathway and UPR pathway. The triple combination
reduces drug resistance by reducing the levels of cellular GSH and suppressing EMT. Gem plus Rom+Cis also
reduces the metastatic related factors, resulted in suppression of metastasis. These effects of the triple combination
on tumors resulted in effective control of tumor malignancy and recurrence.
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5.3 Future Direction
My study revealed that BiP played a role in inducing apoptosis via Gem+Rom+Cis
combination therapy. However, the mechanism behind the role of BiP is not yet clear and further
investigation is needed. BiP has been shown to regulate the activation of 3 major molecules
which regulate 3 branches of UPR pathways including PERK, IRE1α, and ATF6. PERK has
been reported to play roles in apoptosis induction through the eIF2α/ATF4/CHOP pathway [4,
28-29]. IRE1α might induce apoptosis through the XBP-1-TRAF2–JNK pathway [4, 30, 31].
While the mechanism of ATF6 induced apoptosis is unclear, ATF6 has been shown to induce
apoptosis by upregulating the WW domain binding protein 1 (WBP1) [32, 33]. Which of these
three branches is responsible for BiP related apoptosis is still unclear.
I have demonstrated that Gem+Rom+Cis suppressed in vitro invasion of TNBC;
however, the effects of Gem plus Rom+Cis on the in vivo metastasis model still need to be
investigated. The MDA-MB231 cell line has been established and could be used for in vivo
metastasis study. The next step would be testing the combination on the metastasis model. The
underlying mechanism of how the triple combination controls genes related to metastasis, and
effects of Gem plus Rom+Cis on in vivo metastasis models, needs further investigation.
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